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Introduction
Background
At the end of the 1980s and the beginning of the 1990s, a lack of information regarding
appropriate treatment for elderly cancer patients was already apparent [1]. One of the
problems recognized was that knowledge of trearment methods was mainly based on
experience with patients of younger than 70 years, because elderly patients were excluded
from clinical trials [2). Several authors reported differences in treatment by age for
common forms of cancer [3-6|. A significant effect of age was described on the treatment
for breast cancer, prostate cancer and lung cancer. Some studies also addressed the
question of whether there were differences in survival between age groups. In the case of
ovarian cancer, older patients appeared to have poorer survival, also when stage was
taken into account [7,8]. A Dutch study on a large non-selected population of breast
cancer patients found differences in treatment, but not in survival (9|.
In 1995, as part of the annual report, the Regional Cancer Registry Maastricht, which is
kepi by the Comprehensive Cancer Centre l-imburg (IKL), highlighted some forms of
cancer including ovarian cancer. It appeared that remarkable age-specific differences
existed in treatment for women with this form of cancer (10).
This all took place in a period in which the population of the Netherlands, like in many
other Western countries, was ageing rapidly. In the period 1950-1998, the number of
Dun li persons aged 75 years and older increased from 0.2 million to 0.9 million; also the
niimlx-r of persons aged 65-74 years doubled from 0.5 to 1.2 million. The expectanons
tor the future are that the number of persons aged 65 years and older uiU continue to
increase to a maximum of almost 24% of the total population around the year 2040; this
percentage was 13.5% in 1998 [11]. Cancer is predominantly a disease of the elderly: at
present, 45% of all incident cancer patients in the Netherlands are older than 70 years at
diagnosis [12|. As an illustration of the increase in cancer patients as a result of ageing of
the population alone (assuming that incidence rates remain the same) figure 1 presents
the predicted numbers of invasive tumours for the years 2010, 2025 and 2040, with 1995
as the year of reference. The number of incident cancers among persons aged 75-84 years
is projected to increase from 14731 in 1995 to 36354 in 2040 (147%). In persons aged 85
years and older, the number is projected to increase from 4042 in 1995 to 12247 in 2040,
which is a proportional increase of 203%.
45-M SS44 *ST4 TM4<45 15+
Figure 1 Number of invasive rumours in the total Dutch population according to age,
observed in the year 1995 and predicted for the years 2010, 2025, 2040
Source: Netherlands Cancer Registry and Statistics Netherlands; expected numbers were
calculated using the age-specific incidence rates of 1995 as reference
Healthy Dutch women at the age of 70 years have a mean life expectancy of 15 years,
while for men this is almost 12 years fTable 1).
It is obvious that society will continue to be confronted with the burden of cancer in an
increasing proportion of the population, which makes the problem of treating elderly
patients with malignant disease more and more relevant.
Table 1 Mean life expectancy in the Netherlands by age fur males and females
From age Mean life expectancy in years
0 years
50 years
65 years
70 years
75 years
80 years
85 years
90 years
95 years
lOOvcars
Males
75
27
15
12
8
6
5
3
2
1.5
Females
80
32
19
15
11
8
6
4
3
•>
Source: Voorburg, Statistics Netherlands, 2002
Who are the elderly?
In this thesis, more than once it is stated that ageing is an individual process that cannot
be defined by chronological or calendar age [13]. In analyses that examined age, however,
categorical variables have been defined by using calendar age at the time of diagnosis.
Obviously, the definition of'old' or 'elderly' depends very much on the context of where
one stands. In the world of sports, for example, a gymnast of 18 years is almost ancient,
whereas a football player is not considered to be old until he has reached his thirties.
Special glossy magazines arc directed at the 50' group whereas for various social,
economic and medical entitlement programmes 65 years is the traditional age of entry.
Currently, even reaching the age of one hundred years, no longer automatically means
your picture in the newspaper.
In health and medical research, the calendar ages of 70 and 85 years have special meaning.
Especially the age of 70 years is a frequendy used cut-off point in the literarure on cancer
in the elderly. It is assumed that the age of 70 years may well be the chronological
beginning of senescence, because the incidence of age-related changes, such as a decline
of vision and hearing, increases sharply after this age. Along the same lines, the age of 85
years may be considered as the beginning of frailty, a condition in which functional
reserves have practically been exhausted 114].
Owing to the wide heterogeneity within the growing population of older people it has
been proposed to refer to elderly people as the young-elderly (70-74 years), die older-
elderly (75-84 years) and the very elderly persons (85*)[15).
Cancer registry data
Clinical studies, often based on hospital data registries, have the disadvantage that
selection bias due to referral policies cannot be excluded. This problem can be avoided by
using data from a population-based registry, i.e. a systematic collection of data on all
malignant neoplasms occurring in a geographically defined population. All the studies
presented in this thesis arc based on data collected by the Maastricht Cancer Registry,
kept by the Comprehensive Cancer Centre Iimburg (IKL). In two studies data were also
used from other regional cancer registries and in one study data were provided by the
Netherlands Cancer Registry that covers die whole country.
In the Netherlands, cancer data have been recorded since the end of the 1980s at nine
regional cancer registries. All data collected by the regional registries are submitted to the
Netherlands Cancer Registry and stored in a national data bank. Completeness of the
registry is high: more than 95% of all malignancies are recorded [16]. All regional cancer
registries collect data according to a minimum data set, which includes identification
information and tumour information. Coding of the items is based on international
coding rules to facilitate international comparisons of cancer data.
For more information on the regions and registration procedures, die reader is refered to
Schouren et al |17], Parkin [18] and Van der Sanden et al [19].
Aims and outline of the thesis «
Cancer in the elderly is a very broad subject. This thesis concentrates on several aspects
connected to this field of interest. Two objectives form the starting point:
1. Gaining insight into differences in diagnostics, treatment and survival between
younger and older cancer panents and identifying underlying explanations for
these differences.
2. Gaining insight into cancer incidence and cancer mortality in the very elderly
population.
The age-specific variation in treatment for ovarian cancer patients, which was revealed in
the annual report of the cancer registry in 1995, and the increasing interest of physicians
in cancer in the elderly gave rise to the study descnl>cd in chapter 2. This study
concentrated on the differences in diagnostics and treatment l>etwecn younger and older
cancer panents with breast, colorecral, lung, ovarian, head and neck cancer and non-
Hodgkin lymphoma.
To perform analyses on age-specific differences in survival, a form of cancer with a poor
prognosis (ovarian cancer) and a form of cancer with a fairly good prognosis (cervical
cancer) were chosen. Moreover, it was important to have a relatively small backlog when
completing follow-up data on vital status (chapters 3 and 4).
Large differences in treatment for lung cancer between age groups were found in the first
study and the acknowledgement of the lack of information alxmt important prognostic-
factors, such as comorbidity and performance status, formed the background tor the
study described in chapter 5. Thus the influence of underlying factors for age-specific
differences in treatment choice, such as comorbidity and performance stanis, was
examined in patients with non-small cell lung cancer. Then chapter 6 addressed the
cancer incidence and cancer mortality rates in people aged 85 years and older. Cancer
incidence rate and mortality studies often present numbers and rates for elderly patients
aged 70* years or 75' years, and sometimes even 65' years. The main reason for tins is
small numbers or unavailability of more derailed data. The increasing number of very
elderly people has created the opportunity to divide cancer incidence and mortality rates
into distinct age categories, even in panents aged 85-94 years and in patients aged £ 95
years.
In chapter 7, the results of the studies described in chapters 2-6 are discussed and
recommendations are made for further research.
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Summary
In the Netherlands, 45% of all cancer cases occur in men and women aged 70
years and older. Since the population is ageing and cancer incidence rises with age, the
numl>er of new malignancies in the elderly is increasing. It has become apparent that
there is a relationship lx.-rwccn age at diagnosis and the treatment received. Therefore,
age-specific variations in patterns of care for six common forms of cancer in the elderly,
arc examined.
fi///«»/j <W Afr//w</r Patients aged 50 years and older, diagnosed in the period 1988-1992
in Middle and South I .imhurg with breast, colorectal, lung, ovarian, head and neck cancer
and non-1 lodgkin lymphoma were included (N=6911). Data were obtained from the
population based Regional Cancer Registry of the Comprehensive Cancer Centre
Limburg. Age-specific differences in diagnostics and treatment were analysed using chi-
squarc analysis (age categories: 50-59, 60-69, 70"). Ixjgjsac regression analyses were used
to examine the extent to which age increased the chance of not being treated or of
receiving less intensive treatment, while controlling for the stage of the disease and the
sex of the patient.
R«W/.r: For all malignancies the stage was unknown in a larger proportion of the patients
aged 70 years and older than in the younger patient groups. Compared to their younger
counterparts, the diagnosis of elderly breast, colorectal and lung cancer patients was more
often based solely on clinical grounds. In the total study population, 16% were not
treated. I'cr age category' 50-59 years, 60-69 years and 70" these percentages were 7%,
12% and 22% respectively (P-trend=0.001). For all malignancies the chance of not
receiving treatment increased with increasing age. However, the size and nature of the
differences varied with the localisation of the tumour. The proportion of untreated
patients was particularly high in the patients with lung cancer and metastatic colorectal
and ovarian cancer, and there was an increase with increasing age (P-trend=0.001). The
vast majority of patients with NHL, breast, head and neck and non-metastatic colorectal
cancer received treatment, 90%, 94%, 91%, and 99% respectively. However, elderly
patients less often received a combination of treatment modalities.
Gw»r///.r/0».f.' The diagnostics and choice of treatment for several common types of cancer
were dependent on age. This study could not take into account the major problem of
comorbidity which can be a reason to choose for lesser therapy in the elderly. More
research is necessary to determine which factors determine the diagnostics and choice of
treatment and whether these factors differ between young and elderly patients.
/^ jfc Jqpwait* W
Introduction
Steady increases in the survival length of cancer patients and of life expectancy as such in
the Netherlands are expected to lead to an increase in the prevalence of cancer. At
present, over 45% of incident cancer patients in the Netherlands arc older than 70 years
at diagnosis [I]. Very little knowledge is available on the course of disease in the elderly,
or more importantly, on specific treatment policies for elderly cancer patients. Knowledge
about treatment methods is mainly based on experience with patients younger than 70
years. Clinical trials often apply the same age limit |2,3|. In the few studies that included
elderly patients, they were selected on the grounds of not having any cnmorhid
conditions.
Existing literature gives the impression that a greater proportion of elderly patients arc
not treated or receive less intensive treatment (e.g. in terms of monothcrapy versus
combination therapy) than younger patients |4-ll | . In addition, there is hesitance about
administering chemotherapy to elderly patients and, not infrequently, a potentially
curative operation is not performed because the risk is assumed to be too high (12-1S]. It
is not the elderly patients themselves who choose less intensive treatment, although for
them toxicity and quality of life do weigh more heavily |16|. A survey by telephone
revealed that treating physicians were less inclined to offer alternative treatment
modalincs to elderly panents [17].
We performed a study on the differences in diagnostics and treatment Inrrween young and
elderly cancer patients in the Middle and Southern part of the province of I jmburg. The
study group comprised patients with several common forms of cancer: breast, colorcctal,
lung, ovarian, head and neck cancer and non-Hodgkin lymphoma. Besides the high
incidence of these common tumours, variation in treatment modalities was a basis for
selection.
Patients and methods
Data on incident cancer cases and data on diagnostic procedures and treatment were
obtained from the Regional Cancer Registry limburg, a department of the
Comprehensive Cancer Centre limburg (IKI-). This population-based Cancer Registry
covers the regions of Middle and South Iimburg with about 850,000 inhabitants and 8
hospitals (for a description of the region and registration procedures see (18]).
Patients aged 50 years and older who were diagnosed between 1 January 1988 and 31
December 1992 with breast cancer (n=1637), colorcctal cancer (n=1935), lung cancer
(n=2341), ovarian cancer (n=255), head and neck cancer (n=412) or a non-Hodgkin
lymphoma (n= 331) were included in the study (total n=6911). We excluded patients who
had had an earlier malignancy and those in whom the diagnosis had not been made until
autopsy.
The patients were divided into three age categories: 50-59 years, 60-69 years and 70 years
and older.
In the IK)^registry rumour stage is registered according to the TNM classification
system, the Ann Arlx>r staging system for lymphomas and the I'*K»() classification system
for gynaecological rumours [19). Tumour stage referred to the extent of the disease at the
tune of making the definitive decision about the treatment policy. For the current study,
the simplified staging system was used: stage 1, 2, 3, or 4 and stage unknown. For the
analysis of treatment by age, various stages were grouped together on the basis of
similarities in general treatment modalities (see Table 1).
Owing to the fact that in non Hodgkin lymphoma more than in any other malignancy,
classification according to malignancy grade plays a major role in determining the choice
of treatment and the prognosis [20J, thus factor was also included in the analysis.
llic extent ol the diagnostic work-up was derived from the basis for diagnosis and from
the degree of certainty about the TNM classification (certainty factor). The basis for
making the diagnosis was clinical (anamnesis and physical examination), cytological or
histological; the latter was considered to be the most valid. The certainty factor is a
measure of the extent and reliability of the examination procedures used for staging [19).
If there were insufficient data on the tumour (T), regional lymph nodes (N) or distant
metastases (M) in the medical file that part of the TNM was coded CO. The certainty
factor was recorded as Cl when data were available from standard examination
procedures (anamnesis. X-ray photographs), C2 when data were available from more
advanced examination procedures and C3 if surgical exploration had taken place. Per type
of cancer (except for non-Hodgkin lymphomas because no C factor was recorded for
them) we determined the proportion of patients per age category in whom the stage
could be determined but for whom one or more parts of the TNM had a certainty factor
ofO(CO).
Treatment concerned the primary treatment received by the patient in the first three
months after diagnosis, in terms of: surgery, radiotherapy, chemotherapy, endocrine
treatment, other therapy, all possible combinations of these, and no treatment Treatment
policies for patients with lung cancer were analysed separately for small-cell lung cancer
and non-small cell lung cancer patients. Because the distinction between small cell and
non small cell lung cancer is based on the microscopically confirmed morphology of the
tumour, the basis for diagnosis was not analysed separately in order to avoid the risk of
selection bias.
An overview of regular treatment policies for the various malignancies in the IKL-region
was made by two clinical consultants from the Comprehensive Cancer Centre lamburg
(HS, JJ), an internist-oncologist and a radiotherapist-oncologist (see Table 1).
Table 1 General treatment pet malignancy and itagc in Middle jnd South lamburg
Malignancy
Colorccul
hung, non-small cell
Lung, wnall cell
Breast
Or*iy
Head neck
NHL-low grade
NHI.- intermediate/high-grade
Stage
1.11. I l l
I V
I. II, III
IV
Ijirutrd
Extensive
I . I I , 111
IV
I. II. I l l
IV
1,11. Il l
IV
I
II, HI, IV
All
Treatnwnt
Surgery whether or not in combination with radiotherapy
or chemotherapy
Chemotherapy or no treatment
Surgery or radiotherapy or a combination of the two
No treatment
Chemotherapy whether or not ui combination with smgMy
or radiotherapy
Chemotherapy
Surgery whether or not in combination with radiotherapy
or chemotherapy or endocrine therapy
Chemotherapy or endocrine therapy
Surgery in combination with chemotherapy
Chemotherapy
Surgery or radiotherapy in a combination of the two
(chemotherapy or no treatment
Radiotherapy
Chemotherapy whether or not in combination with
radiotherapy
Chemotherapy whether or not in combination with
radiotherapy
For each malignancy we analysed the relationship between age and the extent of the
diagnostic work-up, and between age and treatment by using the Pearson Chi-square test
and the Mantel-Haenszel chi-square test for trend. As the treatment for cancer depends
on the extent of the tumour, for each malignancy we also analysed the relationship
between tumour stage and the age category of the patient. With the aid of models based
on logistic regression (SAS, procedure LOGIST) we evaluated the extent to which the age
at diagnosis of each malignancy influenced the chance of not receiving treatment These
analyses were corrected for the effects of stage and sex.
Results
The total study population comprised 6911 patients (3515 men and 3396 women). The
percentages of men in the lung cancer group, the head and neck rumour group, the non-
I lodgkin lymphoma group and the colorectal rumour group were 91%, 79%, 48% and
49%, respectively.
I*hc diagnosis was confirmed histologically in 88% of the total patient population. Per age
category 50-59 years, 60-69 years and 70* these percentages were 93%, 90% and 83%,
respectively. In the patients with breast, lung and colorcctal cancer there was a significant
increase in the proportion of patients without histological or cytological confirmation
with increasing age, but proportions were very small. For ovarian cancer, 14% of the
diagnosis of elderly patients was based on cytological grounds, while this was only 2% in
the younger age categories. Also for lung cancer, cytological confirmation of the diagnosis
played a fairly major role. In 20% of these patients the diagnosis was confirmed
cytologically (sec Table 3). In the three age categories 50-59 years, 60-69 years and 70*
years, the diagnosis was confirmed cytologically in 16%, 17% and 24%, respectively (P-
trcnd=0.001).
Classification of rumour stage per age category is shown in Tables 2, 3 and 4. For all
malignancies, the stage was unknown in a larger proportion of the elderly patients than
the younger patients. The difference was statistically significant in all the malignancy
groups, except for non-1 lodgkin lymphoma and ovarian cancer (the two smallest groups).
In the colorectal and lung rumour groups, this was associated with a lower proportion of
elderly patients with more advanced stage disease, whereas in the breast and ovarian
cancer groups, the proportion of women with stage 4 disease increased with increasing
age. Furthermore, a relatively large number of young patients with advanced stage head
and neck cancer was found: 41% in the 50-59 year olds versus 26% and 24% in the two
other age categories. This was also rrue for colorectal cancer, 25%, 19% and 17%,
respectively. When the proportion of unknown stages was added, this difference tended
to disappear for the colorcctal group but only partially disappeared for the head and neck
cancer group.
Sometimes the stage of the disease was based on less extensive staging examinations
(certainty factor=0 for T, N or M). This phenomenon was associated with increasing age,
although this was not statistically significant (see Tables 2 and 3).
Table 2 Distribution according to age, stage, diagnostic! and treatment for patients of 50 yean and older wnh head and neck, breast,
colorectal and ovarian cancer, IKi. 1988-1992
Age (yrs)
N
Stage
I
II
III
IV
Unknown
Basis for diagnosis
Histology
Cytology
Staging diagnostics
insufficient*
Treatment Stage Mil
No treatment
Surgcrv (S)
Radiotherapy (RT)
Chcnwtherapv (CT)
Endocrine th.(ET)
S+RT
s+crr
S+ET
Other
Treatment Stage IVNo treatment
Surgerv (SI
Chemotherapy (CT)
Radiotherapy (RT)
Endocrine th.(ET)
S+RT/ET/CT-
Other
Tmtmrni Stage X
No Treatment
Treatment
Treatment •
50-59
111
25%
12".
9%
41%
12%
100%
6%
N51
2%
29*/.
49".
-
16%
_
N46
6%
9%
4%
33%
-
39%
9*4
N14
7%
64%
29*.
Head-Neck
60-69
163
32%
15%
16%
26%
10%
99%
1%
4%
103
3%
22".
55%
-
15%
43
9%
-
26%
-
51%
7%
17
77*.
23%
70"
138
36%
9%
10%
24%
22%
99%
1%
10%
75
7%
21V.
52%
-
-
t7%
_
33
12%
9*4
3%
33%
-
36%
7%
30
13%
77*.
10%
Total
412
31%
12%
12%
30"/.
15%
99%
1%
6%
229
4%
24%
53%
-
-
16%
122
9%
8*4
2*4
30%
-
43%
PA
61
8%
74%
18*.
50-59
488
36%
47%
10%
6%
2*/.
98%
1%
3%
450
.
17*/.
-
0%
1%
37%
7%
12*4
27
-
18%
-
26%
33%
23%
11
9%
91%
-
Breast
6(1-69
552
35%
48%
9%
6%
2%
98*4
1%
3%
507
20*4
0%
0%
1%
3P/.
3%
12%
34
3%
.
15%
-
35%
23%
27*,.
11
9%
82%
9".
70-
597
19%
49%
14%
9%
9%
87%
10%
4%
491
1%
30%
0%
-
14%
16%
2*/.
27%
1M/.
lW7«
51
12%
.
4*4
2%
59%
12%
11%
55
16%
68*.
16%
Total
1637
29%
48%
11%
7%
5%
94%
5%
4%
1448
0%
23%
0%
0%
5%
31%
4%
17%
112
6%
.
11%
1%
44*4
20%
IP'.
77
14%
73%
13%
' Thorouhgness of staging diagnostics, derived from the certainty factor, these percentages ate oni
50-59
293
22%
25%
25%
25%
3%
99%
-
4%
209
2%
81%
0*4
1%
-
6%
P/.
74
P/.
40%
11%
1%
-
35%
S%
10
30%
50%
20*.
IT raid fa
Coiorectal
60-69
600
25%
2P/.
23%
19%
5%
97%
1%
5%
454
!•/.
86%
1%
-
-
4%
6%
115
17%
4P/.
10%
-
-
20%
5%
31
42%
45*4
13%
r me pan
70*
1042
3%
28%
22%
17%
11%
96%
1%
6%
754
1%
90%
1%
-
-
4%
2%
0%
}•/-
I7S
30%
54%
4*4
2%
-
«%
4%
110
61%
17%
12%
enrswB
Total
1935
23%
28%
22%
19%
PA
97%
1%
5%
1417
1%
87V.
1%
0%
-
4%
4%
0%
367
22%
50%
PA
1%
-
16%
3%
151
55%
32%
13%
50-59
54
24%
17%
46%
11%
2%
96%
2%
6%
47
2%
19%
-
11%
-
2%
66%
-
6
.
17%
33%
-
-
50%
-
1
100*.
-
-
lUgp.
Ovary
60-69
90
24%
12%
39%
20%
4%
97%
2%
16%
68
7%
22%
-
13%
-
«%
54%
v/.JV.
18
40*/.
6%
16%
-
-
3PA
-
4
25%
75*/.
70*
111
IP'.
9%
40%
21%
9%
82%
14%
1PA
74
13%
24%
-
19%
-
-
4714
23
26%
9%
52%
-
13%
-
14
50%
3*"/.
14%
Total
255
22%
12%
41%
IP/.
5%
90%
7%
14%
189
PA
22%
-
15%
1%
52%
2%
47
2P/.
P .
36%
-
-
2P/.
-
19
47%
43%
10%
t
I
Table 4 Distribution according to age, *tage, diagnostic* and treatment for patienti of SO yean and older with
a non Hr>dgkin lymphoma. IK).. 1988-1992
Non-Hodgkin I.ymphoma
Agtfrn) 50 59 60-69 70" Total
N 74 105 152 331
Bam for diagnosis
11 otology
Cytology
Stage
1
11
01
rv
Unknown
Malignancy gndc
I^ ciw
Intermediate
high
Not Classified
Treatment Sugr I N
No treatment
Surgery (S)
Radiotherapy (RT)
Chemotherapy (CT)
S+RT
S+CT
RT+CT
Other
Treatment Stage II IV N
No treatment
Chemotherapy (CT)
CT+RT
Other
Treatment Stage Unknown N
No treatment
Treatment
Treatment unknown
The vast majority (94%) of patients with metastatic breast cancer received treatment,
which usually comprised endocrine therapy (44%) or a combination of surgery and
endocrine therapy (20%); however, more of the elderly women only received endocrine
therapy than the younger ones. Nearly all of the patients with metastatic head and neck
cancer were treated (91%). They received surgery and radiotherapy (43%) or only
radiotherapy (30" o); this also applied to the elderly patients. Furthermore, it was found
that in the patients with a metastatic colorecral rumour, more of the women aged 70*
years did not receive treatment than the men within this age category, 40% and 21%,
respectively. Otherwise no sex differences were found.
97%
9%
V *
24*
11%
24%
13*
27%
57%
1%
15%
21
.
14%
5%
19%
9%
14%
24%
13%
44
4%
77H
4%
15%
9
94%
0%
34%
17%
15%
25%
7%
15%
60%
3%
22%
38
24%
13%
29%
16%
8%
8%
2%
60
7%
75%
5%
13%
7
14%
29""..
94*/.
6%
26%
17*/.
18%
22%
16%
10%
59%
5%
26%
40
13%
22%
35%
12%
2%
. 7%
5%
4%
87
16%
57%
8%
19%
25
28%
36" o
36%
95%
5%
30%
18%
16%
24%
12%
15%
59%
4%
22%
99
5%
21%
20%
20%
9%
9%
10%
6%
191
10%
67%
6%
17%
41
19%
32%
49° o
The elderly patients with a non-Hodgkin lymphoma stage I received radiotherapy (35%),
surgery (22%) or chemotherapy (12* o), while the younger patients received more often t
combination of these treatments (see Table 4).
The majority of patients with a non-Hodgkin lymphoim stage 2, 3 or 4 received
chemotherapy, but the percentage decreased with increasing age. In the three age
categories 50-59 years, 60-69 years and 70", the percentages were 77%, 75% and 57%,
respectively (P=0.023). When the malignancy grade was also included in (he analysis (data
not shown), we found that only 10° o of the patients with low grade disease, stage 1
(n= 11), received radiotherapy alone, whereas this percentage was 45" u in the patients with
intermediate or high grade disease. In the patients with low grade disease, stage 2, 3 or 4,
50° o received chemotherapy and 18% were not treated, whereas "M% of the patients with
intermediate or high grade disease, stage 2, 3 or 4 received chemotherapy and 7" o were
not treated. The majority of patients who were not treated were 70 yean of age or older.
Table 5()dd» raooi and 95° o confidence intervals for no treatment according to age,
ad|u3ied for stage and sex, various sites, age SO yean and older. Ikl , 1*)HK I'H>2
Sac Aae(rn) Treatment n , | , | . y , , , 95% CI*
^* " no ye»
HcadNcck 50-59
60-69
70*
Lung, small cell 50-59
60-69
70*
Lung, non-small cell 50-59
60-69
70*
Ovary 50 59
60-69
70*
Non-Hodgkin lymphoma 50-59
60-69
• 95% confidence interval
* Reference category
The logistic regression analyses showed that, corrected for stage and sex, the chance of
not receiving treatment increased with increasing age (sec Table 5). In the colorectal
cancer group, the effect of higher age depended on the tumour stage and the sex of the
patient (see Table 6). The effect of age on the chance of not being treated was greater for
women of 70 years and older than for men. ( )wing to the fact that nearly all of the breast
cancer patients were treated, we investigated die effect of age on the chance of receiving
one treatment modality versus a combination of two or more modalities. The results
showed that a higher age at diagnosis increased the chance of only receiving one type of
treatment (see Table 7).
5
7
13
9
29
49
70
206
418
2
13
23
2
5
26
106
156
125
117
174
114
232
482
441
52
77
H8
72
100
126
1.0
2.7
2.2
5.5
1.4
3.2
3,7
4,7
18
l(rcf)"
(0.3-3.4)
(0.9-7.9)
(0.94.8)
(2.6-11.9)
l(ref)''
(1.0-2.0)
(2.2-4.5)
(0.8-17.5)
(1.1-21.4)
(0.3-9.5)
(1.7 32.2)
Table 6 < Wds ratios and 95% confidence inicrvals for no treatment according to age; patients with colorccul
cancer »««! 5" years and older. IK1. 1988-1992
Age (yrs)
50 59
60 69 '
Age+Slage''
70' 'Stage 1 -III
70' 'Stage IV
70* 'Stage Unknown
Colorectal
Sex
Men
Women
Men
Women
Men
Women
Treatment
\<>
13
99
2
7
19
35
30
Ye*
280
561
346
399
71
ss21
30
(kids ratio
1.6
0.8
1.4
2.8
4.8
2.7
4.6
95°. CP>
l(ref)<
(0.8-3.3)
(O.J-2.5)
(0.5-4.1)
(1.2-6.3)
(1.7-10.7)
(1.0-7.0)
(1.7-12.6)
• Ad|u»icd tut nagc and »ex
'• 95"n confidence interval
' Reference category
•* The effect of age 70* was different for men and women and depended on stage; therefore, the odd* ratios are
presented separately
Table 7 Odds ratios and 95% confidence intervals for one treatment modality versus two or more treatment
modalities according to age; breast cancer, age 50 years and older; IKI., 1988-1992
Site
Breast
Age (yrs)
50-59
60-69
70'
Treatment
One
101
>One
387
419
()dds rano
11
V4
95% Cl
l(ref)'
(0.9-1.6)
(2.6-4.5)
' Reference category
Discussion
Age-specific differences in the diagnostics and treatment of patients with various forms
of cancer, diagnosed in the period 1988-1992, were investigated. Data on incident cancer
cases and data on diagnostic procedures and treatment were obtained from the
population-based Regional Cancer Registry 1 Jmburg.
Several findings indicated that elderly patients had undergone a less extensive diagnostic
work-up: a larger proportion of unknown rumour stage among the elderly, a higher
proportion of patients without a histologically or ecologically confirmed diagnosis, and a
higher proportion of patients in whom the stage was based on less accurate diagnostic
procedures (certainty factor). Furthermore, it could be concluded that a higher age
increased the chance of not being treated or of receiving less intensive treatment.
The extent of the diagnostic work-up was derived from the basis for do^MMfc and from
the degree of certainty about the TNM classification (certainty factor). Our classification
according to the certainty facror was rather rigorous and may have caused some
misclassificanon. For example, a lung rumour which had a CO for M, but C2 for T and C2
for N, which can be enough information to make the decision not to operate, was valued
in this study as being insufficient diagnostic work-up. Also a rather high proportion ol the
certainty factor was missing for one or more parts of the TNM. Nevertheless, an
association was found between the diagnostic work-up according to the certainty factor
and age, suggesting a less extensive work-up at higher age.
The degree to which diagnostics and treatments differed and the nature of these
differences depended on the localisation of the tumour, For head and neck cancer, for
example, there were hardly any age-specific differences in the treatment modalities
applied. It is possible that the heterogeneity within this group of tumours obscured any
differences.
Lung cancer on the contrary, revealed large age-specific differences in the diagnosne
work-up and treatment methods. This was probably related with the fact that lung cancer
still has a very poor prognosis. For example with non metastatu non small cell lung
cancer, older age decreased the likelihood of receiving surgery: 61% of the patients in the
age category 50-59 years were operated on, while this was 50% in the 60-69 year olds and
only 30% in those of 70^ years. A reluctancy to operate on elderly patients was described
earlier by Smith et al. [21| for locoregional NSCLC. They studied differences in treatment
patterns of lung cancer with data from incident cases from the Virginia Cancer Registry,
1985-1989. In their study comorbidity did not appear to have influence. However, over
the past few years, various authors have argued in favour of considering tumour resection
in elderly patients with a non-small cell lung carcinoma |15,22|.
For breast and ovarian cancer, the total of stage 4 and stage unknown is much higher in
elderly patients, which may indicate patient delay. A high percentage of elderly patients
with advanced stage disease is in agreement with some studies (6,23,24) but not with
other (25,26). Especially for breast cancer the literature on the age-stage relationship is
inconsistent (27).
Since the end of the 1980s, it was recommended not to treat elderly breast cancer patient*
with endocrine therapy alone (usually Tamoxifcn) (28-30). This policy was also
recommended in our region and we found that a considerable proportion of the elderly
patients received a combination of surgery and endocrine therapy: 27% for stage 1-3
patients and 12% for stage 4 patients. However, 14% of the elderly patients with breast
cancer stage 1-3 and 59% of the elderly patients with advanced stage disease received
endocrine therapy alone.
In the elderly patients with a metastanc colorectal rumour (n=178), more elderly women
than elderly men did not receive treatment, 40% and 21% respectively, which is in
agreement of earlier findings (8). However, within this wide age category the average age
of the women was higher than that of the men. Probably there was also more comotbid
disease among the elderly women.
< )ne of the factors that is of great importance for the prognosis of a patient with a non-
Hodgkin lymphoma is the malignancy grade. In this study we found that 22% of the
NHL patients could not be classified. Partly this was due to the fact that the diagnosis
was based upon cytology only. Also, there is no classification according to the Working
Formulation for a group of lymphomas which comprise 5% of the total of lymphomas
(e.g. T-cell lymphoma). However, these two phenomena do not completely explain the
high proportion of unclassified lymphomas, which may be partially due to a registration
artefact. Furthermore, we had to be cautious with our analyses on this panent group,
because stratifying the patients according to stage, malignancy grade and age sometimes
produced very small numlx-rs and consequently, dubious conclusions.
()ne of the advantages of using populanon-hased data from a cancer registry is that bias
on (he basis of referral policies is excluded, if for example, patients are recruited for a
study via a hospital registry, there is a risk that this will be a selected group. However, a
cancer registry docs not have at its disposal data on e.g. the dose of cytotoxic drugs
administered, the numl>cr of treatment cycles, possible complications during treatment
and whether the treatment was stopped prematurely. These are all factors diat may be
sub|cct to age-specific differences that were not addressed in this study.
Also we did not have any informanon about comorbidity in our population of cancer
patients, or about their funcnonal and cognitive status, social circumstances and
education level. 'Ihesc factors may have helped to explain why a patient had a less
intensive diagnosne work-up or a less intensive treatment. Advanced stage disease with
the associated series of diagnostic tests may be considered to be too much of a burden by
a patient with poor physical or mental health, or by the family or the treating physician. In
addition, if the treating physician feels defeatism or has misgivings about the efficacy of
the treatment, this may lead to a less intensive policy. In the literature available on this
subject, there is no consensus about the role that these factors play in the choice of
treatment. In some studies, the age effect on the choice of treatment remained intact after
correction for comorbidity |4,8|, while in others the effect disappeared [14]. Within the
group of elderly patients m the USA, associations have been found between no treatment
and civil status, socio-economic status, transport facilities and the distance between home
and the treatment centre |8,30].
In this study we confirmed the existence of age-specific differences in die diagnostics and
treatment of cancer patients. However, we are just as much in the dark about the
decision-making process about diagnostics and therapy in the elderly, as we are about the
consequences of the age-specific differences observed, e.g. consequences for the patient
in terms of survival and quality of life. In a group of breast cancer patients, Bergman et al.
|6| found a difference in treatment between the younger and elderly patients, but not in
survival. Gloeckler Ries [7] on the contrary concluded that for ovarian cancer, there were
differences between treatment and survival: the younger patients had relatively higher
survival chances than the older patients.
If the decision not to treat a patient is based on disease progression and on misgivings
about treatment efficacy |14), then why is it that so many younger patients with more
advanced stage cancer do receive treatment, while the older ones do not? Maybe we are
under-treating the older patients, or over-treating the younger ones? More research is
necessary to provide answers to these questions.
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Age-specific differences in
treatment and survival of
ovarian cancer patients in
the province of Limburg, the
Netherlands
JM dc Rijkc, I.J Schoutcn, A Volovics,
HWHM van dcr Puttcn
Abstract
The objective of this study was to investigate age-specific differences in treatment and
survival of patients with epithelial ovarian cancer diagnosed in the period 1986-92 in
Middle and Southern Ijmburg, the Netherlands.
Data about the treatment of epithelial ovanan cancer patients were derived from the
populauon-based Maastricht Cancer Registry and retrospectively evaluated. Observed and
relative survival rates were calculated according to age, stage, period of incidence and
histology. Differences in survival between three age groups were explored with uruvanare
and multivariate analyses. The patients were followed until 1 |anuary, 1994.
The total study group comprised 367 epithelial ovanan cancer patients, 86 were younger
than 55 years at diagnosis, 152 were 55-69 years and 129 were aged 70 years or older.
Stage III (l*'ICi<)) was the most common stage at diagnosis in the three age groups. Older
women (70') were more likely to have received no treatment or only one treatment
modality than were younger women (P<0.001). I'ive-year relative survival decreased with
age: 54%, 34%, and 17"o in the three age groups 0-54, 55-69 and 70* years, respectively
(P=0.000). Multivariate regression analysis revealed that age at diagnosis was an
independent significant prognostic factor.
Several exposure factors in elderly women may explain the differences in treatment and
survival, such as additional comorbid conditions, more aggressive tumour growth,
' rc/ucfarrcc to ocar efcferrf psrcrcnrs and fcss ravOTa6i'e socrai' concftaons.
Introduction
Ovarian cancer is the fifth most common form of cancer among women in the province
of Limburg, wirh an annual incidence rate of 13.4 per 100,000 women | 1 | . Of all
gynecological malignancies, ovanan cancer is the most lethal; in the province of 1 jmburg,
nearly 63% of gynecological cancer mortality is due to ovanan cancer [I). The incidence
of ovarian cancer increases with age; the highest rates are found berwecn the ages of 65
and 80 years.
Over the last 20 years, the prognosis of ovarian cancer has improved due to a
combination of factors such as new treatment methods and improved supportive therapy
[2,3). However, the majonty of women with the most common type of ovanan
malignancy, epithelial cancer, have advanced disease (stages III and IV) at diagnosis |4,5|.
Several authors (4,6-8), also in the Netherlands [•)] have descnln-d that older ovanan
cancer panents do not receive the same treatment as younger patients. Kldcrly women
were more likely not to have been treated than were younger patients and had more
frequently received only one treatment modality (surgery or chemotherapy). Age specific
survival was examined in several studies [6-8,10-13], but the patients were remitted from
hospital registries [6,7,12] or data were derived from trials |8,1O,11,I3| which may have
led to selected patient groups. In contrast, Hogberg ct al. |14|, lx.'vi et al. | I5 | and (iloec-
kler Rics [3] analysed ovanan cancer data collected by national or regional population-
based cancer registries in Sweden, Switzerland and the United States, respectively. Besides
the examination of treatment patterns, they calculated survival rates and, to account for
noncancer mortality which is higher in the elderly, they computed relanvc survival rates.
They found that younger patients had higher survival rates than older ovarian cancer
patients. Recently, trends in ovarian cancer incidence and mortality have Ix-en studied in
the Netherlands [16], but no comprehensive studies on the diagnostics, treatment and
survival of patients with ovarian cancer have been performed. Different approaches were
employed by van Houwelingen et al. [17] who constructed a prognostic index for long-
term survival of ovarian cancer patients treated with chemotherapy and by Balvcrt-l.ocht
et al. [2] who examined the improvement in the prognosis of ovarian cancer in the
Netherlands over the period 1975-1985.
To obtain further information on the management and survival of ovarian cancer patients
we conducted a population-based study in the province of Iimburg, the Netherlands,
with special attention to the impact of age.
Patients and methods
coZ/ecoo/i
Data on incident ovarian cancer cases and their treatment were obtained from the
Maastricht Cancer Registry, a department of the Comprehensive Cancer Centre JJmburg
(IKL). This population-based cancer registry covers the regions of Middle and South
Limburg, with about 850,000 inhabitants, comprising approximately 5.6% of the Dutch
population (for a description of the region and registration procedures see Schouten et al
[18]).
Information on the survival of all ovarian cancer patients included in this study was
collected by means of active follow-up. The vital status of the patients has been verified
up to 1 January, 1994.
Between January 1, 1986 and Dccemlxrr 31, 1992, 452 women were diagnosed with
cancer of the ovary within the IKI. catchment area. We excluded any patients who had a
previous malignancy (n=35), whose diagnosis had not been made until autopsy (n=2) or
whouc ovarian rumor was of borderline malignancy (n=2); 413 patients were studied.
Because germ cell and sex cord rumors chiefly affect young women and have different
(more favourable) survival rates than epithelial rumors of the ovary, only patients with an
epithelial tumor were included in the analyses (n-367). Serous, mucinous, endometnoid
and clear cell tumours, as well as adenocarcinoma not otherwise specified (NOS), were
considered epithelial tumors.
Despite acuve follow up, 10 cases (2.7%) had to be excluded from the survival analysis,
because no date of last contact or date of death could IK traced.
Variables included age (categories: 0-54, 55-69, 70* years); FIGO (International
Federation of Obstetrics and Gynaecology) stage [19]; histology; period of diagnosis;
treatment and survival data. Tumour stage referred to the extent of the disease at the time
that the definitive decision about the treatment policy was made. Based on comparable
treatment modalities, cases were grouped together for some analyses: stages l + II and
stages III+1V. Time of diagnosis was divided into two categories by calendar year: 1986
through 1989 and 1990 through 1992. This choice was made, not because of a change in
treatment options, but because of small numbers. Treatment referred to the primary
treatment received by the patients in the first three months after diagnosis.
We analyzed the relationships between age and treatment using the Pearson chi-square
test and the Mantel-Haenszel chi-square test for trend. Survival time was calculated from
the date of diagnosis to the date of last contact or death. Observed survival rates were
calculated according to the actuarial method (life-table) [20]. Mortality from compering
causes may bias survival patterns, especially in the elderly. Reliable information about the
actual cause of death was difficult to obtain, which is why relative survival rates were
computed, using the methods and software developed by Hakulincn W <»/. [21]. Relative
survival can be defined as the probability that a cancer patient will survive for a defined
short period, divided by the probability that an age- and gender-matched individual will
survive for the same period [22]. In addinon, length of life expectancy was calculated
using mean death rates and expected lifetimes for the female population in the province
of limburg 1986-1992. Death rates were provided by Statistics Netherlands (CBS).
Differences in relative survival rates between the various age and stage groups were tested
using maximum likelihood ratio tests (23). Observed survival rates were tested tor equality
with the logrank test. To estimate the independent effects of age, stage, histology, penod
of diagnosis and treatment, we performed mulnvanate regression analyses, using PROC
GEN MOD in SAS for relanve survival rates and PROC PIIRl-Xi in SAS for observed
survival rates (Cox model). In PROC GHNMOD, using relanve rates, we calculated
mulriplicanve risk ratios using a Poisson distribution [24).
Panents were sometimes registered as liemg alive on a certain date, but additional
information on their status at the closing daie of the study (1/1/1994) could not be
found. Therefore these cases (N = 18) were censored from the analysis from the last date
of contact (12 were 70 years or older and 9 had stage HI or IV rumors).
Results
We studied 367 patients with epithelial ovarian cancer, ranging in age from 16 to R9 years,
(mean 63; median 65.5). Histological distribution is shown in Table I. About 38"u of the
histologically specified adenocarcinomas were serous carcinomas. Mucinous tumors were
less frequent (11%) as were endomctnoid (7%) and clear cell carcinomas (5"n). A fairly
large proportion of the tumors (36%), however, were registered as ailcnocmmomas
without any further specification; this occurred most frequently in the 70* age group.
Furthermore, the majority (82%) of these unspecified adenocarcinomas were stage III or
IV.
Table 1 also shows the stage distribution by age. FIGO stage III was the most common
stage at diagnosis in the three age groups: 45%, 47% and 46% respectively. Within the
stage categories I+II, the proportion of patients with stage I decreased significantly with
age (P-/nW= 0.034), while within the stage categories 1II + IV, the proportion of patients
with stage IV increased slightly with age (P-/fir»</= 0.425).
Table 1 Epithehal ovarian tumoun dutrilnition according to age group, FIGO stage and histological type
(•'.), Msunmcht Cancer Rripsiry. 1986-1992
N
FlGOstigr
I
11
III
IV
Unknown
Miitol<igical type
Adcnocamnoma N(JS*
Clear cell
rvndiimetrioid
Serous
Murinoun
Un»|H-< lliril
0-54
86(100)
27(32)
6 (7)
39 (45)
13(15)
1 (»)
29(34)
4 (5)
6 (7)
31(36)
15(17)
i <r<
Age(yrs;
55-69
152(100)
31(20)
17(11)
71(47)
29(19)
4 (3)
50(33)
10 (7)
9 (6)
68(45)
14 (9)
1 1
70-
129(100)
18(14)
13(10)
59(46)
27 (21)
12 (9)
55 (43)
3 (2)
9 (7)
41(32)
13 (10)
Total
367(100)
76(21)
36(10)
169 (46)
69(19)
17 (5)
134(36)
17 (5)
24 (7)
140(38)
42(11)
10 (3)
' NOS: not otherwise specified
Standard treatment for ovarian cancer stages I-II was surgery or surgery followed by
chemotherapy [25]. This group comprised 112 patients, two of whom (1,8%) were not
treated (both stage II, age at diagnosis 77 and 79 years, respectively). Large proportions of
both the youngest (51%) and the oldest age groups (48%) were treated with surgery only,
whereas 60% of the patients aged 55-69 years received surgery followed by chemo-
therapy.
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Standard treatment for ovarian cancer stages III-IV was surgery followed by
chemotherapy [25]. This group comprised 238 patients, of whom 32 (13.5%) were not
treated. Per age category 0-54, 55-69 and 70' years, these percentages were 2%, 13% and
21%, respectively (treated w not treated: P-trend=0.002). Furthermore, the proportion of
patients treated with chemotherapy alone increased with age: 22%, 28% and 37%,
respectively (chemotherapy /vr other therapy: P-trcnd=0.06), while die proportion of
patients who received surgery followed by chemotherapy decreased with age: 71%, 54%
and 37%, respectively (surgery+chemotherapy w other therapy: P-trend=0.001).
The stage of disease was unknown in 5% (n=17) of the patients; the majority (n=12) were
70 years or older. About 29% of these patients were not treated, the majority of whom
were 70 years or older.
Table 2 Dutribudon of treatment according to age and stage in epithelial ovarian cancer patients (%). Maastricht Cancer Registry, 1986-1992
Treatment
No treatment
Surgery (5)
Chemotherapy (CT)
S + CT
Other
Total
I I I
-
17(51)
1 (3)
15(45)
-
33(100)
Age
0-54 yrs
Stage
III-IV
1 (2)
3 (6)
11(22)
36(70)
1 (2)
52(100)
X*
-'
1(100)
-
-
-
1(100)
I I I
-
17(35)
1 (2)
29(60)
1 (2)
48(100)
Age
55-69 yrs
Stage
III-IV
13 (13)
5 (5)
28(28)
54(54)
-
100(100)
X
-
-
1(25)
3(75)
-
4(100)
III
2 (6)
15(48)
3(10)
"(35)
31(100)
Age
70* yr»
Stage
III-IV
1«(21)
3 (4)
32(37)
32(37)
1 (1)
X
$ (42)
3 (25)
2 (17)
2 (17)
Total
Sttge
AD
39(11)
61 (16)
80(22)
182(50)
5 (1)
*X= unknown
I
We did not find any differences in the treatment distribution over the two periods of
diagnosis, 1986-89 and 1990-92 (Table 2).
Overall observed survival was 68% after one year, 40% after 3 years and 29% after 5
years. ()vcrall relative survival rates were 70% after one year, 45% after 3 years and 36%
after 5 years. Differences between relative and observed survival rates were most
apparent in the oldest age group, which was to l>e expected (see Table 3). Survival rates
vancd with histology, stage and age. Patients with serous carcinoma had a poorer progno-
sis than those with clear cell, mucinous or endomctrioid carcinoma, with 5-year relative
survival rates of 37%, 56%, 59% and 65%, respectively. When nonspecified adenocarci-
noina was compared to specified adenocarcinoma (serous, mucinous, endomctrioid, clear
cell carcinomas), we found that the 5-year relative survival was 22% in the nonspecified
group r.f 45% in the specified group (P=0.001).
In patients with l'KiO stages I, II, III and IV rumors, 5-year relative survival rates were
90%, 32%, 24".. and 9%. respectively, (P=0.001). Survival rates varied greatly with age
(Table 3). Age differences in relative rates remained valid even after the analysis was
stratified for stages I-II (/>=0.056) and stages III-IV (P=0.0001).
No differences in survival rates were observed between the two periods of diagnosis,
1986-89 and 1990-92.
//7e expecr.fi.ncp
Mean life expectancy in a normal population matched for age and sex was 16.2 years
compared to only 6.7 years (95% CI: 5.5-7.8) in our patients. This corresponded with a
loss in life expectancy of almost 59%. Loss in life expectancy was 35%, 48%, 71% and
85% in women with stages I, II, III and IV ovarian cancer, respectively. In the general
population, women in the 70' age group who were living in the IKL catchment area
between 1986 and 1992 could expect to live for a further 7 years on average. In the 70
years and older patient group, in contrast, life expectancy was approximately 2.5 years
(95% C.I: 1.6-3.3), a decrease of almost 66%. In the youngest group this decrease was
almost 45% and in the 55-69 year group about 59%.
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Table 3 Observed and relative survival rate* of women with epithelial ovarian cancer by age, stage and
htttologr; Maasmcht Cancer Registry. 1986 1992
Overall
Age groups
0-54 yrs
55-69 yn
70' yn
Sage 111
all
0-54 yrs
55-69 yn
70 'yn
Stage 111 IV
an
0-54 vn
55-69 yn
70- yr*
Histology
Adenocarc. NOS'
Adcnocarc. specified"*
Clear cell
Endometrioid
Serous
Mucinous
N
357
85
151
121
111
33
48
VI
230
51
99
80
140
217
16
24
137
40
Ob
lyear
68%
86%
73%
48%
89%
97%
92%
76%
59%
78%
69V.
39*/.
60%
73%
69%
75%
72%
75%
served survv
3ve«r
40%
60%
42%
21%
76%
94%
76%
56%
24%
4(1".
29%
8*/.
26%
48%
61%
64%
42%
56%
val
Sv«r
29%
53%
29%
10*/.
62%
85%
58%
34%
16%
33%
18%
3%
17%
38%
50%
53%
31%
50%
P
value*
0.0001
0001
00001
0.0-
001'
Relative survival
lvcar
86%
74%
52%
91%
97%
93%
81%
61%
79".
66%
43%
63%
75%
70%
78%
74%
77%
3vear
45%
61%
45%
28%
83%
95%
81%
70%
28%
40%
31%
12V.
31%
53%
65%
73%
47%
61%
5vcar
36%
14%
34%
17%
73%
86%
66%
51%
20%
33%
20%
5%
22%
45%
56%
65%
37%
59%
P
value''
0(1001
0.056
0 0001
0.0001
' l<ogrank test
* Maximum Iokclihood Ratio test
* NOS: not otherwise spedfied
* Spedfied adenocarcinomas together clear cell-*- serous-*- mucinous-*- endometrioid carcinoma
' Adenocardnoma NOS m » i adenocardnoma spedfied
Multjvariate regression analyses were performed using the relative survival rates as well as
the observed rates. Variables were age (categorical), FIGO stage (stages II-II, reference
category; stages III-IV; stage unknown), histology (adenocarcinoma specified w
adenocarcinoma NOS), treatment (surgery + chemotherapy yes/no) and period of
diagnosis. In the model that used relative rates, duration of follow-up was defined by a
categorical variable with 8 levels, each of 1 year. However, the 6th, 7th and 8th years of
follow-up were grouped together because of small numbers. When testing for the
significance of individual variables, age, stage and treatment were independent prognostic
factors; histology and period of diagnosis did not approach statistical significance and
were therefore not included in the models.
Rink ratios increased with increasing age with the model that used observed survival rarcs
as well as with the model that used relative rates (see Table 4). In addition, advanced stage
(III + IV) was associated with an increased nsk of dying. Women who had been treated
with a combination of surgery and chemotherapy had better survival rates. When the
model* were applied to the selected group of patients treated with this 'optimal'
combination of treatment modalities, (n=182, of whom 181 were evaluable for survival
analysis), we found that even within this group, age and stage were independent
prognostic factors (sec Table 5).
Table 4 Relative risks (RR) of dying and 95% confidence intervals (CI) estimated with observed and relative
survival rates, according to age, stage and treatment in epithelial ovarian cancer patients;
Maastricht (".smccr Registry. l'W> 1992
Variables
Age groups
0-54 yrs
55-69 yrs
70'yrs
MGO stage
1+11
III + IV
Unknown
Treatment
Surgery +
Chemotherapy
N
85
151
121
111
230
16
181
Model with observed survival rates
RR
l(ref)"
1.59
2.49
l(ref)-
3.61
2.83
0.68
95% CI
1.07-2.37
1.66-3.74
2.41-5.39
1.41-5.68
0.51-0.90
P-value
0.0224
0.0001
0.0001
0.0035
0.0068
Model with relative survival rates
RR
l(ref)'
1.59
2.72
l(ref)'
3.63
2.79
0.66
95% CI
1.07-2.37
1.81-2.39
2.46-5.35
1.42-5.48
0.50-0.87
P-value
0.0001
0.0209
0.0001
0.0030
0.0035
' reference category
Jt
••w-
Table 5 Relative nslu (RR) of dying ami 95*• confidence interval* (Cl) estimated with observed and relative
survival ram, according to age and stage m epithelial ovanan cancer patient* treated with surgery and
chemotherapy; Maascncht Cancer Registry. 1986-1992
Variable*
Age group.
0-54 jm
55-49 jm
70* jm
F1GO Mage
1 + 11
1U+1V
I'nknown
N
51
85
45
53
121
S
Model with
RR
l(ref)«
1.94
2.72
l(«0'
2.54
1.61
observed survival rates
95% Cl
1 14-3 30
1.53-4.83
1.50-4 31
0.47-5.57
P value
0.0143
0.0006
00005
0.4515
Model with relaave survival rates
RR
l(r*Q-
1 %
2.89
l(ref)'
2.47
1 53
95% a
0.14-1.20
163 513
1.46-4.20
O.H2-5 28
P value
0 0131
0.0003
0 00OH
0 V)30
• reference category
Discussion
The present study investigated age-specific differences in the management and survival of
367 women diagnosed with epithelial ovarian cancer. We found that women aged 70 years
and older were more likely to have received no treatment or only one treatment modality
than younger women. In contrast, the majority of younger patients were treated with both
surgery and chemotherapy. Survival analyses showed that the overall prognosis for epithelial
ovanan cancer was poor and even more unfavorable in the elderly patients. (K'erall 5-year
relative survival was 36%, which was in agreement with Balvert-Ixxht [2] and I loglxTg |14]
who reported overall 5-year relative survival rates of 32% and 40%, respectively. In the
present study, 5-year relative survival rates in the three age groups were 54%, 34% and 17%,
respectively. Calculating relative survival rates takes into account mortality from noncanccr-
related disorders, which not only explains the differences between the observed and relative
rates (increasing with age), but also the smaller differences in the relative rates compared to
the observed rates between the three age groups.
The survival of women with serous adenocarcinoma was considerably shorter than that of
women with other specified adenocarcinoma. Two other population-based studies, one in
Iceland [26] and one in Switzerland [15], compared survival rates of epithelial ovanan cancer
of different histological types. In Iceland, women widi endometrioid carcinoma had five-
year survival rates that were similar to those with serous carcinoma, whereas in Switzerland
women with endometrioid carcinoma had a sigmficandy better prognoses than those with
serous cancer, which was in agreement with our findings.
We found that 36% of all epithelial ovanan tumors had no further specification than
adenocarcinoma. In a SEER publication [27], the incidence of adcnocarcinoma NOS and
papillary adenocarcinoma NOS were, in contrast to our study, reported separately, and these
two categories together accounted for almost 30%, which is comparable to our finding.
However, scries with lower proportions of adenocarcinoma NOS were also reported. Levi «/
d/ [15] reported that 22% of epithelial ovarian cancers had not been histotyped, while in a
recent review article in I-ancet [28] Kristensen mentioned only 10% unclassified histotypes,
cited from the 1995 Swedish annual report. In contrast with I>evi <•/ <z/!, the percentage of
epithelial ovarian cancers in our population that had not been histotyped was higher in the
oldest age group.
Although this population-based study had the advantage of an unselected patient group, the
registry did not record data on other important prognostic factors, such as the presence or
absence of residual disease after surgery, malignancy grade and the presence or absence of
ascitcs. In addition, other unrecorded treatment aspects, such as dosage reduction, prematu-
re ending of treatment and complications during or after treatment may lie age-related.
Several possible explananons have Ix-en put forward to explain the differences in survival
Ijctwccn younger and older women with ovarian cancer. First, the unfavorable survival of
elderly patients could Ix' the consequence of more comorbidity among the elderly, which
results in higher (noncancer-related) mortality in this group |6|. Calculating relative survival
rates takes this noncancer mortality into account, but the presence of another illness may
have a major influence on whether a complicated operation should be performed or
burdensome chemotherapy should Ix- administered. Studies in which comorbidity was taken
into account are scarce, but results from trials have shown that the performance status of
patients was an important prognostic factor [10,11,13].
Second, it has been suggested that ovarian cancer may be a more aggressive disease in the
elderly, with earlier development of drug resistance, rumour spread or involvement of vital
organs [2,6|. Currently, there is no direct evidence to support this conclusion.
Third, it has been claimed that elderly women tend to present with more advanced stage
ovarian cancer than younger women [3,29] which was confirmed in our data. Gloeckler Ries
even suggested that older women may have more advanced disease even within stages III
and IV |3|. Surgery (laparotomy), besides being the initial therapy for ovarian cancer, is the
cornerstone of adequate staging. Staging laparoromy is an extensive and fairly complicated
operation that needs a thorough understanding of the pathogenesis of the disease. Although
staging procedures improved the last two decades [2], some reluctance towards the reliability
of the defined stages may still be appropriate.
I'ourth, employing less aggressive or less intensive treatment policies for elderly women has
been put forward as an explanation for survival differences. According to several authors
[7,8,12] older women were more likely to start chemotherapy with bulky disease than
younger women. However, Marcherti tf <// [12] found that the difference in survival
remained valid even within a group of patients who had all received optimum therapy. In
our study, age-specific differences remained valid within the group of patients who had
undergone surgery and chemotherapy. However, detailed information about the
mcriculousness of the operation and the type of chemotherapy was not available.
In summary, differences in treatment cannot fully account for the differences in survival
between younger and older women with ovarian cancer. The most plausible explanation is
that older women are more likely to have exposure to factors that negatively influence
cancer survival, such as a poor physical condition, aggressive rumour growth, reluctance of
doctors to apply standard cancer treatment to older patients and a less favorable social
situation.
In general, physicians agree that all cancer panenfs must be treated equally, regardless of age.
Theoretically this may be correct, but in practice physicians can hardly ignore the age of •
patient, as age is strongly related with other factors that affect treatment choice. Perhaps the
age of the paacnt should be the starting point for the discussion about how to treat that
particular patient, while successively taking all other relevant factors into account.
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Age-specific differences in
treatment and survival of
patients with cervical cancer
in the southeast of the
Netherlands
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Abstract
Age at diagnosis has proven to be an important determinant of the choice of initia
treatment for several sites of cancer. Klderly patients are more likely to receive n<
treatment or less intensive treatment modalities. This study analysed the influence of ag.
on treatment choice and survival in patients diagnosed with cervical cancer.
This population based study used data on 1176 new cases of invasive cervical cance
diagnosed in the period 1986-1996 from three regional cancer registries in th<
Netherlands. All available information on treatment and survival (on |anuary 1" 1998
was recorded- Rclanvc survival rates were calculated according to the Hakulinen methoc
Relative nskt for excess mortality due to the diagnosis of cervical cancer were calculate
with a regression model tor relative survival rates.
I )njy 5% of the patients aged 70 years and older (n=224) were diagnosed with stage L
dlseate, compared to 11% and 30% of the patients aged 50-69 years and 49 years an
younger, respccnvely. Almost 50% of the 70* patients with stage IB-IIA were treatc
w«h radlotHcfupy as a single treatment modality, whereas 64% of the patients <= 4
years wefc treated with surgery. In all age groups, treatment for advanced stage diseas
(itagf > HB) w « radiotherapy alone. No treatment was applied to 10% of the patient
aged ' '0 years ana bide'r, D7& ot inbsc agcu b£A>y\ear3 ana Una 'i'% or^rtbaengca-V^wtt*
and younger. Five-year relative survival was 69% (95% Confidence Interval: 66%-72%)
and differed significantly (p=0.001) with age (70* years: 49%; 50-69 years 58%; <= 49
years: 81" o). Mulrivariatc analyses on a subset of patients showed that age was not an
independent prognostic factor, whereas stage and treatment modality were very important
prognostic factors.
Although elderly cancer patients were sometimes treated differendy from younger
patients, this was in accordance with the guidelines. Relative survival rates differed
significanrly by age. The multivariate analyses on the subset of patients also revealed that
excess mortality increased with age. However when adjustment was made for stage and
treatment, the increase disappeared. The influence of treatment on survival is likely to be
due to the selection of patients based on other characteristics, such as tumour volume,
comorbidity and performance status.
Introduction
The prognostic significance of age in cervical cancer has been the subject of several
studies since the early 1970s. The approach to srudying age at diagnosis as a prognostic
factor has not always been the same. Frequently, the question of whether young patients
have a poorer prognosis than older panents was the central point of interest |1-S|. The
assumpnon was that cancer is biologically more aggressive in younger patients. Other
studies (6,7] associated older age with a poorer prognosis, assuming that elderly patients
receive less aggressive and hence, inappropriate treatment thus influencing their survival
(8J. Several other survival studies on cervical cancer in general or evaluation studies on
screening programmes (9-19] included age as a prognosnc factor in the survival analysis.
Nevertheless, it is soil not clear whether age is an independent prognostic factor in
cervical cancer. To date, very few populanon-based studies have l>ecn published. ()ne of
the advantages of using populanon-based data from a cancer registry is that bias from
referral policies is excluded. Srudies on differences in patterns of care between older and
younger cervical cancer patients are fairly scarce and the emphasis has mostly been on
survival. The present populanon-based study is embedded in a regional pn>|ect on cancer
in the elderly (20-22). The purpose was twofold: firstly, to snidy differences in treatment
patterns for cervical cancer in elderly patients compared to younger patients and secondly,
to study age-specific relative survival.
Patients and methods
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The data for this study were obtained from three regional cancer registries: the
Eindhoven Cancer Registry (eastern part) over the period 1986-1994, the Cancer Registry
of the Comprehensive Cancer Centre East over the period 1989-1995 and the Maastricht
Cancer Registry over the period 1986-1996. The total area represented a population of
around 3 million in 1990. For a description of the regions and registration procedures, sec
Schouten et al [23], Parkin et al (24] and Van der Sanden et al [25].
Data on patients with newly diagnosed invasive cervical cancer registered at one of the
three registries were analysed. Patients who had a previous malignancy other than
basaloid skin cancer, or had been diagnosed at autopsy, or had rumours with a rare
histology (leiomyosarcoma (n=10), endometrial stromal sarcoma (n=2)) or tumours
without a pathological diagnosis (n=3), were excluded, leaving 1176 patients. Information
on the vital status up to January 1" 1998 was collected by means of active follow-up.
Tumour stage was defined according to the 1989 FIGO staging system [26], preferably
based on pre-trcatment information. In 237 cases in whom pre-treatment stage
information could not lie extracted from the medical files, post-surgical information was
used. Patients with pathological stage IIB-IVA (n=27) were assumed to have clinical stage
IB-IIA, as surgery is not the standard treatment for IIB-IVA tumours. Therefore these
patients were included in the analysis as IB-IIA cases [27]. Patients were categorised by
ttagc, which resulted in five categories: IA, IB-IIA, IIB-IVA, IVB and unknown. These
categories were chosen Ixxause treatment guidelines within these stages are uniform.
During the study period, the treatment of first choice for stage IA and IB-IIA was
•urgery, especially in younger patients in order to preserve ovarian function, whereas
radiotherapy was the treatment of first choice for locally advanced disease (i.e. stage IIB
and higher) and in older patients and/or increased operation risk [27].
In this study treatment refers to the primary treatment modality applied during the first
three months after diagnosis. It classified as surgery, radiotherapy, surgcry+radiotherapy
and other/none (other treatment modalities such as chemotherapy / no initial treatment).
Treatment is described according to age and FIGO stage.
Survival was defined as the period between diagnosis and death, irrespective of the cause
of death. As reliable information on the actual cause of death was lacking, correction for
death from competing causes was achieved by computing relative survival according to
the I lakulinen method, using the Finnish Cancer Registry survival software [28]. Relative
survival is defined as the probability that a cancer patient will survive over a defined short
period, divided by the probability that an age-matched individual will survive over the
same period (29). The latter figures were calculated from life tables (supplied by Statistics
Netherlands) compiled according to sex and year of diagnosis in the regional population.
Comparisons between groups were made by means of a likelihood-ratio test. A multiple
regression procedure [30] analogous to the Cox model [31] was used to evaluate the
simultaneous effect of several prognostic factors on relative survival in a selected group
of patients (treated with surgery, radiotherapy or a combination of the two for stage IB-
IVA squamous cell carcinoma and adcno(squamous)carcinoma). Cases with stage IA and
IVB were excluded from these multiple regression models. The former because of a low
number of events (death) and the latter because treatment was palliative and strongly
individualised. Cases with unspecified histology and cases who did not receive surgery,
radiotherapy or both were also excluded, because of low numbers and in order to create a
fairly homogeneous group of patients. Age, stage and treatment factors were introduced
in the models, as well as duration of follow-up (five levels, each of one year duration) and
histological type (squamous cell carcinoma, adeno+adenosquamous carcinoma).
Table 1 Patient charactcnsnct
Total
S«age(HCX))
IA
IB
HA
DB
IDA
DB
IVA
Unknown
Histology
S<|uamous cell ca
Adrnocarcinonu
Carcinoma NOS
Basis for Diagnosis
Cvtolopieal
1 listolo)>ical
< =
N
612
185
278
46
SO
3
18
6
14
12
454
108
SO
2
610
49
• •
100
30
45
8
8
<1
3
1
2
2
74
18
8
<1
UK)
SO-69
N
V40
39
98
54
48
6
46
22
18
9
267
54
19
vr
•.
100
11
29
16
14
2
14
7
5
3
79
16
6
1
70'
N
224
12
SI
34
42
9
33
12
14
17
169
44
I I
10
* .
100
5
23
IS
19
4
15
S
6
a
75
18
5
4
%
Total
N
1176
236
427
134
140
18
97
40
46
38
890
206
HO
IS
1161
100
20
36
It
12
2
8
3
4
3
76
17
7
1
Results - *
Table 1 shows the characteristics of the entire patient population. The distribution of
cases by age reflects the rather young age at which this type of gynecological cancer
occurs. 52% of the cases were aged <= 49 years, 29% were 50 to 69 years and 19% were
70 years or older. More younger patients had early stage tumours, while more older
patients had advanced stage disease. Histological types were equally distributed among the
three age categories. The diagnosis had been histologically confirmed in more than 99%
of the patients of younger than 70 years and in 95% of those aged 70 • years.
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Most of the stage IA cases had been treated surgically (87%). Above the age of 70 years,
the number of cases with stage IA was small (n=12). These 70* patients were treated with
surgery (58%), radiotherapy (25%), or a combination of the two (8%). One of the elderly
patients was not treated.
In the age groups 70* years, 50-69 years and <= 49 years, radiotherapy had been the
single treatment modality in 48%, 25% and 8% of the patients, respectively. For surgery,
these proportions were 22%, 40% and 64%, respectively. Surgery followed by
radiotherapy was received by 27%, 33% and 25% of the panents, respectively (Figure 1).
Some of these patients did not receive curative treatment, especially in the 70* age group
(12.5%). This percentage was 6% in the 50-69 year age group, whereas all patients aged 49
years and younger received curative treatment. Most patients were treated with
radiotherapy alone, i.e. 76% of the patients aged 70 years and older, 86% of the padents
aged 50-69 years and 73% of the patients aged 49 years and younger.
Treatment for women with stage IVB cervical cancer (n=46) was palliative and strictly
individualised (surgery, RT, chemotherapy and combinations of these). A total of 14
patients had not been treated, of whom 3 patients were aged 49 years or younger, 7 were
aged 50-69 years and 4 were aged 70* years.
Figure 1 Initial treatment for patients with cervical cancer stage IB-IIA, 1986-1996;
RT, radiotherapy; Surg, surgery
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Overall relative 5 year survival was 69%. Cumulative relative survival rates at 1, 3 and 5
years after diagnosis, stratified by age and stage, are shown in table 2. Older patients had a
poorer prognosis (I.R test: p=0.000) (Table 2; Figure 2a-2b). The survival difference
between the three age groups was most prominent in patients with stage IIB-IVA disease
(LR test: p=0.008).
Table 3 shows 1, 3 and 5 year relative survival rates stratified by histological type and age.
In the oldest age category, patients with s^uamous cell carcinoma had better 5 year
survival than those with adenocarcinoma, i.e. 54% versus 37%, although this difference
was not statistically significant (LR test: p=0.4).
Univanate and multrv-ariate estimated relative risks of excess mortality are shown in Table
4. Relative nsks for age 50-69 years and 70* years, adjusted for stage and histology, were
both significantly higher than the nsks in the reference category <= 49 years. \XTien
treatment was included in the model, the relative nsks for the three age groups were no
longer significant. •
Table 2 Number of cases (NT) and cumulative relative survival at 1,3 and S yean afat
95° o confidence interval* for the S year rate*, stratified by stage and age
State
IA
IB-OA
HB-rVA
IV'B
Unknown
All stages
Age (yn)
<=49
5049
70*
AH
<=49
50-69
70*
All
<=49
50-69
70*
All
<=49
50-69
70*
AU
<=49
50-69
70*
All
<=49
50-69
70'
All
Natriak
185
39
12
236
324
152
85
561
77
122
96
295
14
18
14
46
12
9
17
38
612
340
224
1176
tyetr
100
100
99
100
95
94
93
95
79
74
56
70
29
39
15
29
100
78
71
82
93
84
71
87
Relative survival (°•)
3 year
99
96
85
98
85
81
80
83
55
46
34
45
20
17
8
14
92
57
68
73
84
66
55
74
5 year
97
95
as
97
SI
T4
TO-
TS
SO
34
30
*7
20
17
14
92
46
59
68
SI
SB
49
69
5 year 95* . O
93-99
80-100
45-100
92-99
76-86
66 81
58 87
7442
39-62
25-43
19 43
31 44
7-48
6-41
7-29
65-99
19 76
29 96
48-85
7884
52-64
41 59
66 72
*CI=Confidcnce interval
Table 3 Number of cases (N) and cumulative relative lurvival at 1, 3 and 5 yean after diagnosis;
95% confidence intervals for the 5-year rates strab6ed by histologkal type and age
l lutuiom
Squamous cell
carcinoma
Adenoctrcinoms
Carcinoma not other
witc specified
AKe(yrs)
<=49
50-69
70*
AB
<=49
50-69
70*
All
<=49
50-69
70*
All
Natruk
454
267
169
$90
101
*
44
207
so
19
11
Ro
Relative
1 year
93
86
72
87
96
86
68
88
84
64
66
survival ("•)
3 year
84
67
60
75
87
64
39
72
82
59
31
~i i
5 year
80
58
54
67
83
56
37
69
82
60
23
- ( i
5 year 95% CI •
76-84
52-65
44-65
66-73
75-90
42-69
20-60
61-76
70-91
38-80
6-61
59-80
• CI=Omfidencc interval
Figure 2a Relative
rates by age. cervKal c a n c e r s
1BUA
Figure 2b
5/

Discussion
This registry-based study addressed age-specific patterns of treatment and survival in
panents newly diagnosed with invasive cervical cancer. Age at diagnosis strongly
influenced treatment choice, whereas stage of disease and rreannent were the most
strongly determining factors for survival.
In our study populanon, the older panents had more advanced disease than the younger
patients. The same phenomenon has also been described in other snidies and it is
considered likely that in the older age group, this can l>e attributed to patient delay, fewer
programmes that provide or promote screening and less compliance with recommended
screening praences p.12,32].
In accordance with the guidelines, most patients received either radiotherapy (31%) or
surgery (44%) as single treatment modality. In almost 17% of the cases, surgery revealed
indications for post-operative radiotherapy. In total, 4% of the panents did not receive
any initial treatment (70* years: 10%; 50-69 years: 5%; <= 49 years: 1%). The most
commonly applied treatment in elderly panents with clinical stage IB IIA disease was
radiotherapy alone. Surgery as a single treatment was the most common in younger
patients with stage IB-IIA disease, sometimes with adjuvant radiotherapy. These findings
are in agreement with those of other recent studies |17,1')]. In contrast with surgery alone
and radiotherapy alone, the proportion of panents with stage IB-11A who received
radiotherapy after surgery was almost equal in the three age groups (Figure 1). In this
situation, however, RT after surgery will not always have been adjuvant RT. When
positive lymph nodes were found during surgery, two scenarios were feasible: 1. Surgery
was only explorative and RT was given as the initial treatment. 2. Radical surgery was
earned out, followed by post-operative adjuvant RT. This implies that within this
treatment group, there were cases with a pathologically proven worse prognosis that
received RT as the initial treatment.
We found fairly large differences in treatment choice between patients with early stage
disease, but this was not the case in patients with advanced stage disease (FIGO IIB-
IVA), the majority of whom were treated with radiotherapy alone, irrespective of their
age, which has also been reported by other authors [16,32].
We looked at survival differences by age. Five year relative survival was 81% in women of
49 years or younger, 58% in women aged between 50-69 years and 49% in women of 70
years and older (p=0.00). These percentages are similar to those published in other large
series of patients with cervical cancer [32,33]. The poor outcome in the oldest age group
was partly related to their unfavourable stage distribution: 5-year survival in stage IB-IIA
panents did not differ significantly between the age groups, but it did differ significantly
in stage IIB-IVA patients.
To further analyse the effect of age, stage, morphology and treatment on survival,
multiple regression analysis was used to estimate relative risks for excess mortality. The
results in table 4 illustrate very clearly the interdependency of age, stage and treatment.
Age was an important prognostic factor in the model without treatment, but it did not
have any significant influence on survival when treatment was included in the model.
However, in observarional studies, it is very hard to estimate any real differences in
outcomes between groups that received different treatment, because prognostic
characteristics will not be equally distributed over the groups [34].
There is general agreement that radical surgery is equally as effective as radical
radiotherapy for the treatment of early stage invasive cervical cancer [32]. Therefore the
effect of treatment on survival is probably the result of patient selection on specific
fearures/characteristics within the treatment and stage groups such as tumour volume,
comorhid conditions and performance status. Unfortunately we did not have any
information about these items.
It should Ixr noted that when we calculated relative survival rates, all cases were included.
In contrast, the muhivanate analysis excluded cases who had not received treatment.
Especially elderly patients were highly represented within the latter category.
A population-based study in Sweden [14] revealed lower survival rates in older patients
with cervical cancer than in younger patients (period 1960-1984, n= 17377), but nothing
was mentioned about stage at diagnosis. Although the authors regarded a more advanced
stage at diagnosis in older women to be a major cause of the difference in prognosis, they
also suggested that a lower proportion of human papilloma virus-associated tumours in
older patients independent of stage, might explain the age-related differences in survival
because those tumours carry a better prognosis than rumours without any identifiable
human papilloma virus nucleic acids. However, the mulbvanate analyses in our study do
not support this hypothesis, because they showed a very low influence of age on survival
in Norway [13] reported on 7429 panents diagnosed with cervical cancer (period 1971-
1990). Besides studying incidence and mortality trends, they conducted a multivariate
analysis on relative survival rates, including stage, time and age. They found that there was
a tendency towards a poorer prognosis in younger women, but age was not an important
prognostic factor (p=0.08). In a patterns of care study in the US on cervical cancer
patients diagnosed in the year 1984 (n=59O4) an inverse relationship was found between
survival and increasing age at diagnosis which was largely attributed to the unfavourable
stage distribution in the elderly [32].
In our study we also looked at survival stratified by histology and age. In contrast with
most authors [13,17,35-37], but in concordance with others [16,38] we did not find
significant differences in survival between squamous cell carcinoma and adenocarcinoma,
cither overall or in specific age groups.
We can conclude that the elderly cancer patients in our study were generally treated in
accordance with the guidelines, although we did not have any detailed information about
symptoms, radiotherapy doses or complications following treatment. Does survival in
elderly cervical cancer patients give reasons for concern? We found that relative survival
rates differed significantly by age. However, the mulnvariate analyses on a subset of
patients showed that age per se did not have an independent prognostic effect on
survival, but that stage and treatment were the explanatory factors. It is very likely that the
effect of treatment was due to pancnt selection based on other characteristics, such as
tumour volume, comorbidity and performance status.
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Influence of age,
comorbidity and
performance status on the
choice of treatment for
patients with non-small cell
population-based study
JM de Rijkc, L| Schoutcn, GPM ten
Velde, SI. Wanders, KCM Bollcn,
RI Lalisang, |AAM van Dijck,
GWPM Kramer, PA van den Brandt
Abstract
w: In the Netherlands in 1997, 43% of patients with newly diagnosed lung cancer
were older than 70 years, l^arge age-specific differences in treatment exist, especially for
non-small cell lung cancer. We examined whether age, comorbidiry, performance status
and pulmonary function influenced treatment according to the prevailing regional
guidelines.
/><//»>»// W wr/Wr: Data on patients with newly diagnosed non-small cell lung cancer
(N=8O3) in the period 1997-1998 in the eastern and southern part of the Netherlands
were obtained from the population-based cancer registries of the Comprehensive Cancer
Centre Mast and the Comprehensive Cancer Centre Iimburg. Additional data on
comorbidiry, performance status and pulmonary function (FEV1) were collected, as well
as detailed information on initial treatment.
Age specific differences in treatment according to the guidelines were examined.
Adjusted and non-adjusted odds ratios were calculated by means of logistic regression
analyses.
K/W/.r: 82"" of the patients with stage 1 or II disease received treatment according to the
guidelines; this applied to only 48% of the patients with stage III A disease and to 54% of
the patients with stage IIIB disease. For all stages, this proportion decreased with
increasing age. In stage IV disease, 36% of the patients did not receive any treatment; this
applied to 52% of the elderly patients (75* years). Multivariate analyses only showed
associations between comorbidiry and treatment choice for the localised stages. No
associations were found with performance status. Age of 75* years appeared to be the
most important factor for not receiving treatment according to the guidelines.
Cortr/wwm: A substantial proportion of elderly patients with non-small cell lung cancer did
not receive standard treatment. Performance status and comorbidiry seldom formed the
underlying reasons for not treating elderly patients according to the guidelines. Calendar
rather than biological age seemed to play the most important role in the choice of
treatment for patients with non-small cell lung cancer.
In t roduct ion
Lung cancer is a major health problem in the Netherlands, as it is in almost every Western
country. Forty-three per cent of patients with newly diagnosed lung cancer are older than
70 years | l j . A previous study showed that more elderly patients with various forms of
cancer often did not receive any treatment or received less extensive treatment than their
younger counterparts |2|.
I-arge age-specific differences in the diagnostic procedure and treatment methods were
especially found in non-small cell lung cancer.
The presence of concurrent health conditions, also known as comorbidincs, is seen as
one of the most important reasons not to apply the standard therapy. Without
comorbidity adjustment, it can be argued that any apparent age bias in decision making is
only a reflection of the poorer general health of older patients. In earlier studies, effects
were found even after adjusnng for comorbidiry |3) or performance status |4|. This
strongly suggests that physicians are basing their decisions on calendar age rather than on
biological age. Populanon-based studies on age-specific treatment differences in non-
small cell lung cancer patients are scarce and very few have addressed several important
prognostic factors, such as comorbidity, performance starus and pulmonary function in
association with the actual treatment received |5|. In the present study, clalx>ratc
treatment data (e.g. dose of radiation received) were retrieved from the medical files.
While taking into account the regional treatment guidelines, we analysed the influence of
age, comorbidity, performance status and pulmonary function on the choice of treatment
for non-smati cell lung cancer patients.
Patients and Methods
Data on patients with newly diagnosed non-small ceil lung cancer were provided by two
regional cancer registries: the cancer registry department of the Comprehensive (lancer
Centre East (1KO) for the period 1 January ro 1 June 1998 (n=2H3) and the Maastricht
Cancer Registry, department of the Comprehensive Cancer Centre I-imburg (IKL) for the
period 1 May 1997 fo ! May 1998 (n=52O). The total area represented a population of
around 2.1 BBBJOO in 199?. AH cases not confirmed to be small cell tumours were
considered as being non-small eel! lung cancer, including those without
hisfotagkaf/cytotogcai confirmation. This means that in some cases the stage could not
be defined (stage not applicable).
As this study addressed determinants of frrsitrnent choice in a non-selected population,
we also included pasiriifs whose lung cancer was not their first primary malignancy (15%
of the total study group). Registration clerks actively collected data on all the patient!
from the medical records. In addition to the standard cancer registry itemi on diagnosis,
stage and trasal tgeaonen*, exfrfwive ireaoiKnf daa were documented, such us the total
dose of radkaherapy received, c«mori>fclify, performance m m i and pulmonary funcfion
(Forced Expiratory Volume in 1 second (FiiVJ)).
Jf>
Data on comorbidity and performance status were extracted from previous hospital
admissions, letters of referral or discharge to general practitioners, the medical history,
current medication and preopcradve assessments. Comorbidity was recorded using a
slightly adapted list of serious diseases developed by Charlson and associates (see
Appendix 1) [6]. Having an earlier malignancy also forms pan of the Charlson
comorbidity index.
Different rating systems are used in oncology to assess performance status, i.e. a patient's
functional capacity to work and perform daily activities: the Karnofsky scale [7], the scale
described by Zubrod |8] which has been adapted by the Eastern Oncology Group
(EC(XJ) and the World Health Organisation (WHO). The registration clerks recorded all
the rating systems used by the specialists; for the analyses, the different scales were
translated into the WHO scale (sec appendix 2). Although performance status is
recognised as being an important prognostic factor in patients with lung cancer [9) this
item is not well-documented by physicians. Therefore the registration clerks had to
estimate a patient's performance status on die basis of medical history reports written in
the medical files by physicians and nurses.
In lung cancer patients, pulmonary function assessment forms pan of the standard
diagnostic procedure. To estimate the influence of this item, the forced expiratory volume
in 1 second (FF.V1) and the diffusion capacity for carbon monoxide (DI.CO) were
recorded. In the analyses, only the FILV1 was used, however, because DLCO was missing
in the majority (54%) of cases.
Clinical Ktiytr .i.< xmwlnd ly thr .agnAtcics juxatdinj.' to .thr .raittenr XMM xlassificvrinp
system. A new edition of the TNM classification was published in 1997 and became
widely available in 1998 |10). In the present study, however, the 1987 edition [11] with
adaptations from 1992 112] was used, because the prevailing regional treatment guidelines
for non-small cell lung cancer, published in 1997 [13] were based on the 1992 TNM
classification. The subsequent changes in the TNM classification have already been
mentioned. The most important adaptation was that a T3 tumour without positive lymph
nodes (NO) was classified as stage IIIA, while in the new version, this is stage IIB.
Patients staged as cMx were not considered to have distant metastases (cMO), provided
that T and N were known.
Guidelines valid in the 1K.I. region [13] dated back to April 1997, while those in the IKO
region were from 1988 [14]. The guidelines in the two regions were compatible, although
those in the IK1. region were more specific. The latter definitions were used in our
analyses, in order to make differences and variations more visible and concrete.
Table 1 Definitions of treatment according 10 the guidelines by stage
TNM i n g Intention Treatment according u>
Sogcl II (T1-2N0 I MO) Cunnve • Sunken-, including k>cal excision, lobectomjr
and pneumectomy
• Radiotherapy (RT) 60 Gy (2 Gy fractjoni) or
SI Gy (3 Gy tractxxu)
Sage HI A (Tl -2 N2 MO, Long locoregional control • Surgery + / RT
T3 N0-2 MO) • Radiotherapy 60 Ciy (2 Ciy rncaont) or SS Gy
(2.5 Gy fractions) +/• chemotherapy
Stage 1MB (any T N3 MO; Locorcgional control • Surgery + / RT
T4anyNM0) . lUdiotherapy 50 Gy (2 Ciy fraction.) or 40 Ciy
(2.5 fractions) +/- chemotherapy
• Rad»therapy40 49C;y(2C;yfracnonii)or *)
39 Ciy (Kir fractioni)
Stage IV (any T any N Ml) Palliation « Radiotherapy
On the basis of detailed information on the treatment received in the fint three months
after diagnosis, we examined whether patients had been treated in accordance with tin-
guidelines (stage I+II, IIIA, MB). Treatment definitions per stage according to the
guidelines are given in Table 1. For stage IV, we examined which patient* received
palliative treatment and which patients did not
Adjusted and unadjusted odds ratios for whether or not treatment had been received
according to the guidelines were calculated by means of logistic regression analyses (SAS,
procedure LOGIST). As treatment guidelines are defined by stage of disease, subgroup
analyses were performed for patients with stage I I I , stage IIIA and stage MB, and stage
IV. Variables included in the models (backwards, alpha 0.05) were age (0-59 years
(reference category (ref)), 60-74 years, 75* years), sex, comorbidiry (no concomitant
disease (ref), 1-2 concomitant diseases, 3 or more concomitant diseases), performance
sums (0 (ref), 1-2, 3-4, unknown), FEV1 (<2.5 L(rcf). >2.5 L, unknown) and Cancer
Registry (1KO/IKL). For stage IIIA, a variable for T3 NO tumour (no positive lymph
nodes) was included (yes/no), because of the changes in TNM versions.
Results
The total study population comprised 803 patients widi non-small cell lung cancer. Eighty
per cent of die patients were male and 20% were female; 51% were aged between 60-74
years and 27% were aged 75 years or older. Table 2 shows some relevant patient
characteristics stratified by age group. Proportions of stage IV decreased with increasing
age, while proportions of stage unknown or not applicable increased with increasing age.
tf/
The proportion of patients with one or more comorbidities increased with increasing age
and the proportion of patients with a good performance status was lower among the
elderly patients.
Table 2 Patient characteristics NSCIX! (1997-1998) stratified by age group
Age (yrs)
Sex
Women
Men
Stage
i
nIHA
1MB
IV
X,NA«
Histology
l-argc cell carcinoma
Squamou* cell carcinoma
Adenocarcinoma
Other*
No histological vcrificarinn
Gomorludity (no)
0
1
2
3>
Unknown
Performance status
0
1
2
3
4
Unknown s
Region
1KI.IKO
Total
<=59
N(%)
69 (39)
107 (61)
35 (20)
4 (2)
32(18)
35(20)
61 (35)
9 (5)
48(27)
51(29)
62 (35)
11 (6)
4 (2)
106(60)
38(22)
16 (9)
4 (2)
12 (7)
99 (56)
20(11)
14 (8)
5 (3)
2 (1)
36(20)
112(64)
64(36)
176(100)
60-74
N <%)
73 (18)
338 (82)
111(27)
3 (1)
67 (16)
72(18)
113(27)
45(11)
77(19)
168(41)
110(27)
27 (7)
29 (7)
99(24)
152(37)
86(21)
54(13)
20 (5)
181 (44)
80(19)
30 (7)
13 (3)
5 (1)
102 (25)
267 (65)
144(35)
411(100)
75-
N(%)
23(11)
193 (89)
57 26)
3 (1)
31 (14)
40(19)
50(23)
35 (16)
35 (16)
100(46)
36(17)
19 (9)
26 (12)
43(20)
73(34)
48(22)
42 (19)
10 (5)
79 (37)
53 (24)
19 (9)
6 (3)
3 (1)
56(26)
141 (65)
75 (35)
216(100)
Total
N(%)
165 (20)
638(80)
203 (25)
10 (1)
130(16)
147(18)
224 (28)
89(11)
160 (20)
319 (40)
208(26)
57 (7)
59 (7)
248 (31)
263 (33)
150 19)
100(12)
42 (5)
359 (45)
153(19)
63 (8)
24 (3)
10 (1)
194 (24)
520 (65)
283 (35)
803(100)
• X= unknown (n=27); NA= not applicable ((n=62) (no histology n=59; tumour cells not otherwise specified
(NOS) n=3));
>• Other: tumour cells NOS (n=3); carcinoma NOS (n=32); carcinoma undiffcrcntiated NOS (n=3);
pseudostitvomatous carcinoma (n=l); carcinoid NOS (n=6); neuroendoenne carcinoma (n=6);
•denogquamous carcinoma (n=6)
Table 3a Patient characwiisbc* >tagc I I I , IIIA, IIIB NSCLC and distribution of treatment (not) according to the guideline*
Age
<=59 years
60-74 years
75* years
Pulmonary Function (FEV1)
0.5-1.0 L
1.1-2.4 L
>=2.5L
Unknown
Therapy
No therapy
Surgery
Radiotherapy (RT)
Surgery+RT
Chemotherapy (CT)
RT+CT
S+CT/S+RT+CT
Comorbiditv (number)
0
1
2
3>
Unknown
Performance stain*
0
1
2
3-4
Unknown
Comprehensive Cancer Centre
1K1.
1KO
Total
Not accor.
Guidelines
N(%)
1 (3)
15(13)
21 (35)
3(25)
19(17)
7 (10)
8 (35)
24(100)
-
11(25)
-
1(50)
1(100)
-
2 (3)
13(18)
11(23)
8(27)
3 50)
16(12)
5(16)
3(60)
13(26)
24 (16)
13(20)
37(17)
Stage III
According
Guidelines
N(%)
38(97)
98(86)
39(65)
9(75)
91 (83)
60(90)
15 (65)
-
123(100)
33 (75)
19(100)
-
-
-
54(95)
60(82)
36(77)
22(73)
3(50)
110(87)
26(84)
2(40)
-
37(74)
124(83)
51(80)
175(82)
Total
N
39
114'
60
12
no
67
23
24
123
44
19
2«
57*
73
47
30
6
127-
31
5
-
50
149-
64
213(100)
Not accor.
Guidelines
N(%)
13 (41)
31(46)
22(71)
5(83)
30(45)
17(47)
14(64)
21(100)
-
28(49)
-
9(100)
2 (17)
6(100)
21(51)
25(54)
6(43)
10(50)
4(44)
27(45)
16(50)
5(71)
5(83)
13(56)
41(54)
25(46)
66(51)
Stage IIIA
According
Guidelines
Nf •)
19(59)
35(52)
9(29)
1(17)
36(55)
19(53)
7(32)
-
16(100)
29(51)
8(100)
-
10(83)
-
20(49)
21(46)
8(57)
9(45)
5(56)
34(55)
16(50)
2(29)
1(17)
10(44)
34(45)
29(54)
63(48)
Total
N
32
67 •
31
6
66
36
22-
21
16
57
8
9
12
6
41
46
14
20-
9
62*
32
7
6
23
76*
54
130000)
Not accor.
Guideline*
N(%)
13(37)
28(39)
27(67)
4(50)
33 (51)
8(27)
23(52)
45(100)
-
13(18)
-
9(100)
-
1(100)
18(34)
26(59)
12(46)
8(42)
4(80)
22(37)
20(56)
6(37)
3(75)
17(55)
42(47)
26(46)
66(46)
Stage UIB
According
Guideline*
N(%)
22 (63)
44(61)
13(33)
4(50)
32(49)
22(73)
21(48)
8(100)
58(82)
4(100)
9(100)
35(66)
18 (41)
14(54)
11(58)
1(20)
38(63)
16(44)
10(63)
1(25)
14 45)
48f53)
31 (54)
79(54)
Total
N
35
72
40
8
65
30
44
45
8
71
4
9
9
1
53
44
26
19
5
60
36
16
4
31
90
57
147
Treatment of one patient was unknown
In the patients with stage I or II disease, 82% received treatment according to the
guidelines, i.e. surgery or radiotherapy (Tables 1 and 3a). However, the proportions
decreased with increasing age, from 97% in the age group 59 years and younger, to 86%
in the age group 60-74 years and to 65% in the age group 75 years and older.
Surgical procedures (n=142) were lobectomy (64%), pneumectomy (31%) and smaller
resections (5%) (data not shown). In this group, 95% of the patients without any serious
concomitant diseases and 73% of the patients with three or more concomitant diseases
were created according to the guidelines. More patients with a good performance status
(WHO grade 0) received treatment according to the guidelines then patients with a
poorer performance status (WHO grade 1-2). In a logisne regression model, the factor
age of 75 years or older was associated with higher proportions of patients who did not
receive treatment according to the guidelines (OR=8.5; 95% CI 2.2-32). Also the
presence of comorbidiry appeared to significantly influence the treatment of this group of
lung cancer patients (Table 5). After adjusting for the other variables, ORs for
performance status were no longer significantly increased.
T a b l e 3 b Pat ients w i t h N S C 1 . C no t treated a c c o r d i n g t o the g u i d e l i n e s (stage I II. I I I . \ , 1MB)
Stage 111
N o therapy
R T < 6 0 Ciy (2 Ciy fract ions) o t
< 51 Ciy (3 Ciy fract ions)
CT/RT+CT
Subtotal
Stage III A
No therapy
RT < 60 Ciy (2 Gy fractions) ot
< 55 Ciy (2.5 Ciy fractions)
Chemotherapy (CT)
Surgery (S)+CT
Radiotherapy (RT)+CT
S+RT+CT
Subtotal
Stage MIR
No therapy
Radiotherapy «• 30Ciy
Chemotherapy
S+RT+CT
Subtotal
<= 59 years
N (•••)
-
1(100)
-
1(100)
4 (31)
2 (15)
2 (15)
2 (15)
2 (15)
1 (8)
13(100)
6 (46)
1 (8)
6 (46)
13(100)
to
60-74 years
N <•••)
9 (60)
4 (27)
2 (13)
15(100)
5 (16)
17 (55)
6(19)
2 (6)
1 (3)
31(100)
16(57)
9(32)
2 (7)
1 («)
28(1 (XI)
75* years
N (%)
15 (71)
6 (29)
21(100)
12 (55)
9 (41)
1 (4)
-
•
22(100)
23 (85)
3 (11)
I («)
27(100)
Total
N (%)
24 (65)
11 (30)
2 (5)
37(100)
21 (16)
28 (42)
9 (14)
4 (6)
2 (3)
2 (3)
66(100)
45 (66)
13 (19)
9 (13)
1 (2)
68 (100)
tf*
About 48% of the patients with stage I1IA NSCLC received treatment according to the
guidelines, i.e. surgery with or without radiotherapy, radiotherapy alone or in combination
with chemotherapy (Table 1 and 3a). More patients aged 75 years and older had not been
treated according to the guidelines (71%) than their younger counterparts. In the
umvarute as well as the mulrivanate analyses, age was the most important risk factor for
not receiving treatment according to the guidelines (Table 5). The presence of one or
more comorbidiries, or other variables such as performance status and pulmonary
funcnon did not show any significant association with not receiving treatment according
to the guidelines. In panents without positive lymph nodes (T3N0) the risk of not being
treated according to the guidelines was significantly lower than in the other categories of
stage M A (OR 0.08, 95% Cl: 0.03-0.33).
Fifty-four per cent of the patients with stage M B disease received treatment according to
the guidelines, i.e. surgery, radiotherapy, a combination of the two, or RT with
chemotherapy (Table 1). In panents aged 75 years and over, this proportion was lower:
33% (Table 3a). The large majority (73%) of stage MB patients who were treated
according to the guidelines received radiotherapy alone; 2'J out of these SH patients
received a palliative dose (not shown). In the univanate analysis, age of 75 years and over,
pulmonary function (FEV1 < 2.5 L or unknown) and the presence of one or rwo
comorbidiries showed a significantly higher risk for not receiving treatment according to
the guidelines (Table 5). However, in the mulnvanate analyses, none of these factors
remained significantly associated with the risk of not being treated according to the
guidelines.
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Table 3b shows the patients with stage I+II, M A and M B who had not been treated
according to the guidelines: 37 patients with stage III NSC1X! had not been treated
according to the guidelines and 24 had not received any treatment, all of them were 60
years or older. Radiotherapy with less than a total dose of 60 Gy (2 (iy fractions) or 51
Gy (2.5 Gy fractions) had been received by 11 patients, whereas one patient had received
RT in combination with chemotherapy and one patient had been treated with
chemotherapy alone.
Fifty-one per cent of the stage MA patients did not receive treatment according to the
guidelines. In this group, 28 patients had received radiotherapy alone, but a total dose of
less than 60 Gy (2 Gy fractions) or 55 Gy (2.5 Gy fractions); 17 patients received
chemotherapy with or without another modality, but not according to the guideline*,
while 21 patients (16%) did not receive any treatment. In contrast with stage MA, a large
proportion of the stage M B panents were not treated at all (66%) and this percentage
increased with increasing age. Treatment consisted of radiotherapy with a dose of less
than 30 Gy (19%) or chemotherapy (13%).
In the years 1997 and 1998 there was no clear standard treatment for stage IV NSCLC
Survival rates were low and treatment was administered for palliative purposes. Table 4a
shows the proportions of patients who received treatment and those who did not. No
treatment had lx*en applied to 36% (n=76) of the patients. This proportion differed by
age group: 20% of the panents aged 59 years or younger had not been treated, 34% of the
patients aged 60-74 years and 52% of those aged 75 years or older. Patients who had been
treated mostly received radiotherapy (n=94) or chemotherapy (n=30) (Table 4a). Table 4b
presents treatment by age and whether radiotherapy was locoregional, to metastases, or
both. The proportion of patients that received radiotherapy to metastases decreased with
increasing age: 43% of the patients aged 59 years or younger, 26% of the patients aged
60-74 years and 18% of the patients aged 75 years and over. Chemotherapy was mostly
administered to younger patients and consisted of regimens with gemcitabine.
Logistic regression analysis for whether or not treatment had been received revealed that
an age of 75 years or older and an FEV1 of lower than 2.5 L or FEV1 unknown was
related to not receiving treatment.
u/iArnown/ nor a/j/>//ca/>/e'
Twenty-seven patients had stage unknown because of an incomplete diagnostic
procedure- and in 62 patients there was no histological classification, which means that
their stage could not be defined. In this group, 80 out of the 89 patients were aged 60
years and older. The majonry (54%) had not received treatment and this proportion
increased with increasing age: 33% of the panents aged 59 years and younger, 49% of the
patients aged 60-74 years and 66% of those aged 75 years and over. In the total group
who received treatment (n=41), 15% underwent surgery and 25% received radiotherapy
(results not shown).
I x)gisric regression analyses (results not shown) indicated that the factors age 75 years or
older (OR 2.9; 95% CI: 1.3-6.6). performance status of WHO 3-4 (OR 2.4; 95% (II: 1.0-
6.0) or unknown pulmonary function (OR 3.4; 95% CI: 1.5-7.3) were associated with stage
unknown or the absence of histological classification.
Table 4a Padcni charactenMics stage TV NSCLC, treatment or no treatment
Age
<=59jrear»
60-74 years
75* yean
Pulmonary Function (FEV1)
US-1.01.
I.1-Z4L
>2.51.
Unknown
Therapy
No therapy
Surgery
Radiotherapy (RT)
Surgery+ RT
Chemotherapy (CT)
RT+CT
Unknown
Coroorbtdity (no)
0
1
2
3>
Unknown
Performance status
0
1
2
3-4
Unknown
Comprehensive Cancer Centre
IKL
IKO
Total
Table 4b Treatment for stage IV
Treatment
No treatment
Surgery
Radiotherapy (RT) locoregjonal
Radiotherapy metastases
Radiotherapy both
Chemotherapy
Unknown
Total
No treatment
«2(20)
38(34)
26(52)
3(43)
32(36)
4(12)
37(39)
76(100)
-
-
-
-
-
25(32)
26(37)
14(33)
6(33)
5(33)
26(32)
12(29)
11 (41)
5 (33)
22(37)
47 (33)
29(35)
76 (34)
NSCIX: by age
<= 59 years
N (%)
12 (20)
1 (2)
6(10)-
26 (43)*
4 (6)'
11 (18)
1 (1)
61 (27)
Stage IV
Treatment
48(79)
72(64)
22(44)
4(57)
54(61)
28(85)
56(59)
-
4(100)
94(IOU)
3(100)
30(100)
11(100)
•
53(67)
44 (63)
26(62)
11(61)
8(53)
55(68)
29(71)
16 (59)
10 (67)
32 (53)
90(64)
52 (63)
142 (63)
Age
60-74 yean
N (%)
38 (34)
3 (3)
12 (11)
30 (26)
10 (9)
15 (13)
5 (4y
113 (50)
Treatment
unknown
1 (2)
3 (3)
2 (4)
3 (3)
1 (3)
2 (2)
-
-
•
-
6(100)
1 (1)
2 (5)
1 (6)
2(14)
-
-
6 (10)
4 (3)
2 (2)
6 (3)
75* yean
N(%)
26(52)
4 (8)
9(18)
4 (8)
4 (8)
3 (6)
50(22)
Total
61
113
90
7
»
53
95
76
4
94
3
30
11
6
76
70
42
18
IS
82
40
27
15
59
141
83
224(100)
Total
N(%)
76(34)
4 (2)
22(10)
65(29)
18 (8)
30(13)
9 (4)
224(100)
' one patient received RT + chemotherapy
' one patient received Surgery + RT and 5 patients received RT + chemotherapy
' one patient received S + RT
* two patients received RT but the localisation and dose was unknown
Table 5 .Adjusted and unadjusted Odds Ratios (OR) wkfa 95% confidence interval () for treatment of NSCLC not according to die guidelines
(stage III, IIIA, IIIB) and for no treatment (stage IV)
Age
<= 59 Yean
60-74 years
75* yean
Pulmonary Function
(rfcv i)
<2 .5L
>= 2.5 L
Unknown
Comorbidirjr
0
1-2
3>
Performance StttM
0
1-2
3-4
Unknown
TNMT3N0
Yes
No
(Comprehensive
Cancer Centre
IKO
IKL
Stage III
Unad) OR
l(ref)
3.2(0.9-11)
1Z8 (3.5-46)
1.5(0.7-3.1)
l(ref)
2.4 (0.9-6.8)
l(ref)
6.5(27-19)
87 (2.4-28)
l(ref)
3.1 (1.4-6.8)
.
1.2(0.5-2.6)
Adj. OR
l(reQ
27(0.6-8.1)
8.5 (27-32)
1.0(0.5-2.3)
l(reO
2.4 (0.7-8.3)
l(ref)
4.8(1.5-15)
5.7 (1.5-21)
l(ref)
Zl (0.9-4.9)
0.8(0.3-19)
Not Applicable
l(reO
1.1(0.5-2.0)
Stage IIIA
Lnadj OR
l(ref)
1.3(0.6-3.0)
3.6(1.2-10)
1.1 (0.5-2.3)
l(ref)
2 7 (0.7-6.8)
l(ref)
1.0(0.5-2.3)
0.9 (0.3-2.5)
1 (ret)
1.5(0.6-3.3)
6.3 (0.7-57)
1.6(0.6-4.3)
0.1 (0.0-0.4)
l(ref)
l(ref)
0.7 (0.3-1.4)
Adj. OR
l(ref)
1.2(0.4-3.4)
3.9(1.1-14)
0 9 (0 J-Z6)
2.5 (0.6-10)
l(ref)
1.3(0.5-3.2)
0.7 (07-27)
l(ref)
1.8(0.7-4.6)
2.9 (0.3-30)
1.5(0.5-4.9)
0.08 (0.0-0.3)
l(ref)
Stage IIIB
Lnadj. OR
l(ref)
1.1 (0.5-23)
3.5 (1.3-9.1)
2.8(1.1-7.1)
l(ref)
3.0(1.1-87)
l(ref)
2.3(1.1-4.8)
1.9(0.7-5.1)
l(rei)
1.7(0.8-3.7)
57 (0.5-52)
2.1 (0.9-5.1)
Adj. OR
l(ref)
0.8(0.3-2.1)
27 (0.7-6.8)
2.3 (0.8-67)
l(reO
1.9(0.6-5.8)
l(ret)
1.9 (0.8-4.4)
1.3(0.4-4.0)
l(ref)
1.5 (0.7-3.4)
5.3 (0.4-64)
2.1 (0.8-5.7)
Not applicable
l(ref)
0.9(0.4-1.9) #
Stage IV
Unad) OR
l(reQ
2.1 (1.0-4.4)
4.7(2.0-11)
4.2(1.4-13)
l(ref)
4.6(1.5-14)
l(ref)
1.2 (0.6-27)
1.2 (0.5-3.0)
l(ret)
1.1 (0.5-2.1)
1.1 (0.3-3.4)
1.4(0.7-3.0)
Adj. OR
l(ref)
2.1 (0.9-5.0)
5.1 (2.0-13)
3.9(17-12)
l(ref)
4.7(1.4-15)
l(ref)
0.8(0.4-1.7)
0.7 (0.3-1.8)
l(ref)
0.9(0.4-1.8)
0.9 (0.2-3.3)
1.3(0.6-2.8)
Not applicable
l(ref)
1.1 (0.6-1.9) #
# variable not included in the final model
Discussion
The present retrospective study investigated treatment patterns for non small-cell lung
cancer panents in the eastern and southern pan of the Netherlands. 1-ess than half the
patients with a stage I, II, III A or 1MB disease (44%) were treated according to the
guidelines. Adherence to treatment guidelines was highest in stages I-II and decreased
with increasing age. The majority of panents with stage IV disease received palliative
treatment for palliation (63%), but the proportions varied by age group: 79% in the age
group 59 years and younger, 64% in the age group 60-^4 years and 44% in the age group
75 years and over.
After adjustment for the effect of age and cancer stage, the influences of comorbidity and
performance status on treatment choice were less than expected. In the univartatc
analyses, significant associanons with comorbidity and performance status were only
found for the localised stages. Poor pulmonary function (FHVI) was associated with not
receiving palliative treatment in stage IV patients, even after adjustment for age,
comorbidity and performance status.
Several factors should be considered when interpreting these findings. First, comorbidiry
data, performance status and pulmonary function (FF.Y1) were not part of the standard
registration items at the rime of data collection (comorbidity was included in 1999). This
means that registration clerks were not used to documenting these items. To record
comorbidity. methods introduced by the adjacent cancer registry in Kmdhoven (IK/)
were used. 'ITiey have been recording comorbidiry since 1993 and a validation project has
been carried out [3]. To evaluate the data on comorbidity in the present study, the
prevalence of comorbidity in lung cancer patients was compared to the outcomes of the
IKZ study (3|. Differences were in a range of 1 to 6% for both men and women in seven
out of eight categories.
Second, even though great effort was made, information on performance Status and
FEV'l was difficult to obtain from the medical files. In 14% of the cases it wa» clear that
no FEV1 test had been performed, while in 12% of the cases the notes in the medical
files were not clear about the performance of pulmonary function tests. In !x)th
categories, the performance status was coded as unknown (percentage by age group: <=
59 years: 20%, 60-74 years: 25% and 75* years: 26%).
Comorbidity significandy influenced treatment for the early stage non-small cell lung
cancer. This might be related to the fact that the prevalence of comorbidity in patients
with a stage I-II NSCLC was higher than that in patients with more advanced lung cancer
(Table 2). This phenomenon was also found by Jansscn-Heijnen et al |3| , who ascribed it
to screening bias, e.g. lung cancer was diagnosed at an early stage as a result of regular
monitoring of other chronic diseases. This might also explain the high proportion of
elderly patients with stage I-II at diagnosis, although this could be partly the result of
understaging due to less extensive diagnostic procedures [2].
In the present study, stage was classified according to the 'old' TNM classification |12|. In
the new TNM classification (10). cases with T3N0 (no positive lymph nodes) arc
classified as IIB instead of IIIA. This change in TNM classificanon was made because
apparendy, these patients have better survival and should be offered treatment with
curative intent.
In the present study, T3N0 patients were analysed in more detail, because physicians may
have been aware of the more favourable prognosis and have treated them according to
the new staging classification (15). Compared to the other stage IIIA patients, more T3N0
patients had been treated according to the guidelines. A fairly large proportion of the
other stage IIIA patients had received radiotherapy to a lower total dose than advised in
the guidelines (n=28), or they had received no treatment at all (N=21); die majority of the
latter patients were aged 60 years and older.
There are no curative treatment options for patients with metastasised lung cancer (stage
IV). Radiotherapy administered for palliation of severe respirator)' symptoms or for
metastases causing severe complaints was a generally accepted treatment policy.
Therefore the characteristics of the patients who received such treatment (to prolong
survival or for symptomatic relief) were compared to those of the patients who did not
receive any treatment. This comparison revealed different proportions by age group: 44%
of the patients aged 75 years and over received some kind of palliative treatment, mostly
radiotherapy, whereas this was 64% in the age group 60-74 years and 79% in patients
aged 59 years and younger. Relatively fewer elderly patients received radiotherapy for
metastases.
Clinicians who managed elderly patients with lung cancer may have felt cautious about
referring them for radiotherapy. In the study period 1997-1998, research specifically
performed to assess the problems and benefits of radiotherapy for lung cancer in elderly
patients was scarce |16|. Patterson et al retrospectively studied 149 lung cancer patients
aged 75 years and over. They concluded that palliative radiotherapy was well tolerated and
the response was similar to that in younger patients. Other studies have also indicated
that (radical) radiotherapy can be applied to elderly people without increased toxicity [17-
20]. However, heterogeneity among individuals increases with increasing age, and more
than in younger cancer patients, all therapeutic options should be considered in relation
with careful evaluation of the patient (functional assessment, comorbidiries, stage of
disease, social situation, individual wishes for therapy, etc.) (21,22]. Another positive
development over the past few years is that most clinical trials no longer specify upper
age limits. Unfortunately the recruitment of elderly patients in trials is still low [23].
Especially in the younger age groups with advanced stage NSCL, chemotherapy seemed
to occupy a fairly important position in the treatment options; 30 patients received
chemotherapy alone and 11 received both radiotherapy and chemotherapy. At time of the
study, 1997-98, the role of chemotherapy in stage IV NSCLC in everyday practice was
still uncertain and did not form pan of the 1KI. or IKO treatment guidelines. However,
in 1995, the results of a meta-analysis on randomised trials revealed an increase in median
survival of about 6 weeks and a 10% improvement in 1-year survival compared to
patients managed with supportive care only [24]. In subsequent years it has become dear
that several chemotherapy regimens could offer a small increase in 1-year survival and a
delay in symptoms that cause quality of life deterioration in elderly and unfit pabents [25].
These developments led to changes in the IKL treatment guideline [26] by making
chemotherapy part of the standard treatment, although it is still advised to do this in trial
settings.
In the present study, performance status did not seem to play a major role in treatment
choice, which is in agreement with Brown ct al |4] who studied differences in treatment
for 563 lung cancer panents in the L'K. \X'e found that performance status as such was
often not even mennoned in medical files. Besides, the percentage of panents with a very
poor performance status (3-4). was low. Only 4%> had a performance status of 3-4
(proportions were higher in patients with stage IV (7" o) and stage unknown (1U° o)).
Our study population included 89 patients with unknown stage, partly because of lets
extensive diagnosne procedures (N=27) and partly because the diagnosis was not
histologically confirmed (N=62). The high prevalence of comorbidines and the poor
performance status of these patients may indicate that the diagnostic procedure was less
extensive because of comorbid condinons or low performance status which implicitly
meant that patients were not considered to be candidates for standard treatment. In some
cases, this may have been the result of the misunderstanding that extensive clinical staging
in the elderly is not worthwhile (27). It seems likely that from the very Ix-gimung ot the
diagnostic process, there was no intention to treat these patients according to the
guidelines. Obviously, there will sometimes be very good reasons not to perform
extensive diagnosne procedures, or not to treat a patient according to the standard
guidelines (e.g. lower RT dose). From the documentanon of the reasons for treatment
choice, it was learned that occasionally the disease was progressing too rapidly or
sometimes the treatment-related complications were considered unacceptable.
Nevertheless, in the literature there are strong indications that a nihilist approach from
physicians plays an important role [28] and that the numl>cr of patients who refuse
treatment is very small [29].
In the present study, the calendar age of the patient was the most important factor upon
which physicians based their therapy decision. Fairly large proportions of elderly patients
were not treated, were undertreated or were withheld some form of treatment for
palliation. Exclusion of elderly patients from former cancer trials and lack of data
concerning the benefit of treatment for elderly patients with cancer may have played a
role in treatment decisions.
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Appendix 1
Classification of co-morbidity, according to an adapted version of the list
developed by CharUon et al. (1987)
COPD
Cardiovascular disease (myocardial infarction, cardiac decompensation, angina pectoris,
intermittent claudication, abdominal aneurysm)
Ccrebrovascular diseases (cerebrovascular accident, hemiplegia)
()thcr malignancies (except for basal cell skin carcinoma)
Hypertension
Diabetes Mcllitus (medically treated)
Other
Soft tissue diseases (Bcsnier Boeck disease (sarcoidosis), Wegener's granulomatosis, SLE
(systemic lupus crythematosis)
Rheumatoid arthritis (only severe)
Kidney diseases (chronic glomerulonephriris, chronic pyelonephritis)
Bowel diseases (Crohn's disease, ulcerarive colitis)
I Jver diseases (cirrhosis, hepatitis)
Dementia
Tuberculosis
Appendix 2
WHO (Zubrod) scale
0 Normal activity
1 Symptoms, but nearly fully ambulatory
2 Some bed rest, but needs to be in bed for less than 50% of normal
daytime
3 Needs to be in bed for more than 50% of normal daytime
4 Unable to get out of bed
References
|. Visser O, Coebergh PX"Vt/. Schoutcn I.J. et al: Incidence of cancer in the Netherlands 1997. Utrecht,
Ycrcniging van Integrate kankcrccntra, 2001.
2. Dc Ri|kc JM. Schouten I.J, Schoutcn HC, et al: Age-specific differences in the diagnostics and
treatment of cancer patients aged 50 yean and older in the province of lomburg. the Netherlands.
.-U» O«m/7677-685. 1996
J. Jansscn-Hei)nen MIJG, Schipper RM, Razenberg PPA. et at: Prevalence of comorbidity in lung
cancer paoents and its relationship with treatment: a population-based study ' J " « C-rtrw 21:10^-
113,1998.
4. Brown JS, Kraut D, Trask C, et al: Age and the treatment of lung cancer. 7'Awuv SI :S64-S68, 19%
5. Smith TJ, Penberthy I, Desch (J-., et al: Differences in irunal treatment patterns and outcomes of
lung cancer in the elderly i^rig Cowr 13:235-52 , 1995
6 Charlson MF., Pompei P, Ales KI, et al: A new method of classifying prognostic comorbidity in
longitudinal studies: developments and validation / (Ann» /)w 40:373-383, 1987.
7. Kamofsky DA, Abelman \X1I, (braver l.F, ct al: The use of nitrogen mustard in the palliative
treatment of carcinoma with particular reference to bronchogenic carcinoma ( <j/*rr I, I')4K
8. /ubrod CG. Schncidcrman M, Frei 1% et al: Appraisal of methods for the study of chemotherapy in
man: comparative therapeutic trial of nitrogen mustard and tncihylcncthiophosphoramidc / < Ana
/>u 11:7-33, 1960
9. Pacsmans M, Sculler |P, Libert P, et al: Prognostic factors for survival in advanced non-small cell
lung cancer umvanate and mulnvanate analyses including recursive partitioning and amalgamation
algorithms in 1,052 patients y (.*« O*W 13:1221 -1230, 1995.
10 Sobin I.H, Wittckuid CM, eds. TNiW Gku^mte* ^Af*fe»M/ 7/uwwn. (ed Fifth edition). New
York, VC'tley-ljss. I'ICC International Union Against Cancer, 1997.
11. Hcrmanek P, Sobin I.H, cds. TNAf ft&un^vAofl o/ Mi/jigiM*/ 7Vmw/x, (ed Fourth, Fully Revised).
Berlin, Springer-Vcrlag, UICC International Union Against Cancer, 1987.
12 Mermanek P, Sobin I.H, eds. 77VAf CXir/z/n-d/to* «/ A/dimwit/ 7««m«nr, (ed Fourth edition, 2nd
revision). Berlin, Springer -Verlag: UICC International Union Against (dancer, 1992.
13. duidclinc for diagnostics and treatment for carcinoma of the lung (in Dutch). Maastricht,
Werkgroep Bronchuscarcinomcn, Intcgraal Kankcrccntrum l.tmburg, 1997.
14. Ciuidelinc for treatment: Non-small cell lung carcinoma. Nijmegcn, Comprehensive Cancer Centre
Fast, 1988.
15. Van Dijck JAAM, Festen J, Dc Kleijn F.MHA, et al: Treatment and survival of patients with non-
small cell lung cancer stage III A diagnosed in 1989-1994: a study in the region of the
Comprehensive Cancer Centre Hast, the Netherlands. />"»? CJ*<w»r 34:19-27, 2<X)1.
16. Patterson CJ, Hocking M, Bond M, ct al: Retrospective study of radiotherapy for lung cancer in
patients aged 75 years and over. ^ f ^ » » ^ 27:515-8, 1998.
17. Lonardi F, Coeli M, Pavanato C>, et al: Radiotherapy for non-small cell lung cancer in patients aged
75 and over safety, effectiveness and possible impact on survival. L««K C^ wwirf 28:43-50, 2000.
18 Pignon T, Scalliet P: Radiotherapy in the elderly. / ;«•; .V/wj O W 24:407-11, 1998.
19. Pignon T, Gregor A, Schaakc Koning C, ct al: Age has no impact on acute and late toxiciry of
curative thoracic radiotherapy. K*M!K)M«-O»m/46:239-48, 1998.
20. Olmi P, Ausili-Cefaro (> Radiotherapy in the elderly: a muloccntnc prospective study on 2060
patients referred to 37 Italian radiation therapy centers. Riijr/22:53-6, 1997.
21. Extermann M: Measuring comorbidity in older cancer patients. /;*r/ C^ imrr 36:453-71, 2000
22. Aapro M, Extermann M, Repetto L: Evaluation of the elderly with cancer. / !«• OIKS/ 11:223-9,
2000.
23 Rocha Lima CM, Hemdon Jl., 2nd, Kosry M, et al: Therapy choices among older patient* with lung
carcinoma: an evaluation of two trials of the Cancer and 1-eukemia (iroup B. C^»«r94:]Kl-7, 2002.
24. Non-small Cell I Aing Cancer Oillaboratrve C>roup: Chemotherapy in non-small cell lung cancer a
meta-analvsis using updated data on individual paoenrs frr>m 52 randomised clinical trials. BAf/
311:899-909.1995
25. The elderly Lung (dancer N'morelbine Italian Study Group: Effects of vinorelbine on quality of life
and survival of elderly patients with advanced non-small cell lung cancer. 7 Aid// Cawr/- //»// 91 66-72,
1999.
7i
26. Guideline for diagnostics and treatment for carcinoma of the lung (in Dutch). Maastricht,
Wcrkgroep Bronchuscarcinomen. Intcgraal Kankercentrum I jmburg, 2000.
27. Van Mccrbceck JP: Staging of non-small cell lung cancer: consensus, controversies and challenges.
L*/« Or«r 34:S95-S107, 2001.
28. Gaudcn SJ, I. T: The curative treatment by radiation therapy alone of stage I non-small cell lung
cancer in a geriatric population L*/r£ G/»</r 32:71-79, 2001.
29 The AM: TJnr<//tor»/ /or /w/iSw/ro/r <m/ /w/lor/divrtw iDuwnw/wton. (in Dutch). Houten/Diegem, Bohn
Suflcu Van Loghum, 1999.
Cancer in the very elderly
Dutch population
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Abstract
Cancer incidence and mortality rates rarely are studied in people age >= 85
years. Usually, patients ages 65 years, 75 years, and 85 years of age are combined into 1
group, because of small numbers. The number of people age >. 85 years in the
Netherlands increased from 99,000 in 1976 to 203,000 in 1995 (an increase of 105%).
The growth of the total population in this period was only 13%. This study addressed
cancer incidence and mortality rates among the very elderly in the Netherlands.
Af*/A»<&: Cancer mortality data (1976-1995) and population data were obtained from
Statistics Netherlands, whereas cancer incidence data (1989-1995) were provided by the
Netherlands Cancer Registry. Cancer incidence and mortality rates were calculated and
trends in cancer mortality were studied.
R/W/r Total cancer incidence rates were highest in the age group 85-94 years, in men and
women (3466/100,000 person-years and 1604/100,000 person-years, respectively)
Prostate carcinoma was the most frequent cancer in men ages 85-94 years, followed by
colorectal carcinoma. In women ages 85-94 years, colorectal carcinoma was mosi
frequent, closely followed by breast carcinoma. In the 95* years age group squamous cell
skin carcinoma was the most frequent cancer in both men and women, followed by
prostate carcinoma in men and breast carcinoma in women. Cancer mortality rate?
increased with increasing age to nearly 3700/100,000 person-years in men age 95* yean
and to 25(X)/100,000 person-years in women age 95* years. In men, lung carcinoma was
the most frequent cancer-related cause of death in patients age < 85 years, whereas in
older men this applied to prostate carcinoma. In women, breast cancer was the most
frequent cancer-related cause of death in all age groups above 55 years. Cancer as a cause
of death became less prominent with increasing age. Over the period 1991-1995, 42% of
deaths in men ages 55-64 years were attributed to cancer versus 52% of deaths in women
(total population); these proportions in the 95* years age group were 11% and 7%,
respectively.
(Vowi/w/o/w: Peak incidence rates of major cancers were found in the very elderly
population in the Netherlands. Different rrends in age-specific mortality rates of
individual cancer sites were found, with stable rates in the middle age groups and
increasing rates in the oldest age groups. This may reflect a real increase caused for
instance by changes in mortality from other diseases and/or an artifacrual increase caused
by increased cancer detection rates in the (very) elderly.
Introduction
In the Netherlands, the number of persons age > 85 years increased from 99,(HH) in 1 976
to 203,000 in 1995 (an increase of 105%). It is predicted that bv the \-ear 2015 the total
population living in the Netherlands will have increased by 8.4%, from 15.4 million in
1994 to 16.7 million [1). However, the segment of the population age 65' yean is
expected to grow much faster (45° o), although the proportion of persons age > 85 years
will remain the same.
In 1995, > 5% of all new male and nearly 8% of all new female cancer cases in the
Netherlands were diagnosed in patients age >. 85 years |2). Because cancer predominantly
is a disease related to old age, the number of cancer cases can IK expected to increase
dramatically in the future. Compared with 1994, an overall increase has Ix-en predicted in
the absolute numbers of patients with cancer of common sites such as colon, lung, breast
and prostate for the year 2015, varying from 30-60% |3|.
Cancer incidence rate and mortality studies often present numbers anil rates lor "the
elderly" in panents age 85* years or 75* years, and somenmes even as young as 65* years.
The main reason for this is the small numbers or unavailability of more detailed data. The
increasing number of very elderly people, sometimes referred to as the "oldest old",
created the opportunity to divide cancer incidence and mortality rates into disnnct age
categories in patients ages 85-94 years and in patients age .> 95 years. The currect study
presents cancer incidence rates and cancer mortality rates in the very cldctly population u\
the Netherlands.
Materials and methods
Znc/V/e/Jce
Incidence data regarding persons age ^ 55 years for the years 1989-1995 were provided
by the population-based Netherlands Cancer Registry, for which 9 regional cancer
registries collect data. All invasive and in situ malignancies, including nomnvasivc bladder
carcinoma diagnosed from 1989 onwards in people living in the Netherlands, have been
registered nationwide [4]. We studied only invasive tumors; in situ bladder rumors ffis)
and papillary noninvasive bladder tumors (T \) were not included.
Due to privacy regulations and the absence of a personal identification number, death
certificates cannot be used as an additional source of notification of cancer cases in the
Netherlands. Despite the lack of this notification source, the infrastructure of the
Netherlands health care system and the notification procedures used have made it
possible to establish a cancer registry with high completeness (96.2%), also in the highest
age groups [5,6].
In the case of multiple tumors, the same rules were applied as those recommended by the
International Association of Cancer Registries [7]. In brief, a rumor only is included in the
incidence rates if the localization (based on the first three numbers of the 9* revision of
the International Classification of Diseases (ICD-9) or the histology (divided into eight
groups) is different from the other rumors in the same panent. Lateralizanon and the rime
between the development of the first and second rumors do not play a role.
a/a
Cancer mortality data were provided by Statistics Netherlands. This organization receives
mortality data from death certificates that are filled in by physicians. For the period 1976-
1995, we received data concerning the number of deaths in the Netherlands with the
underlying causes of death coded according to the ICD-9 (malignancies: 140-208) and
subdivided by gender, 5-year age categories (ranging from birth-4 years to 100* years),
and date of death (1976-1980,1981-1985,1986-1990,1991-1995).
Annual population data by gender and 5-year age categories (ranging from birth-4 years to
100' years) for the period 1976-1995 also were provided by Statistics Netherlands. Highly
reliable population data can be obtained from Statistics Netherlands because all
demographic changes arc recorded at the municipal level. In 1976, the Netherlands had
an average population of 13.7 million (6.8 million males and 6.9 million females). In 1995
the average population had grown to 15.4 million (7.6 million males and 7.8 million
females). Although the birthrates dropped to the European average after 1970, the Dutch
population is still relatively young compared to other European countries (48% of
individuals are between 15-44 years of age). However, the number of people age >. 65
years is growing rapidly (1.3% annually compared with an annual growth of 0.6% during
the last decade).
Approximately 9% of the population is comprised of ethnic minorities (mainly from
Indonesia, Surinam, the Netherlands Antilles, Turkey and Morocco). Life expectancy in
the Netherlands is among the highest in the world; during the period 1991-1995 it was
74.3 years for males and 80.2 years for females.
Using the average population in 5 age groups (55-64 years, 65-74 years, 75-84 years, 85-94
years and 95' years) in the separate periods, the age-specific incidence and mortality rates
were calculated as the annual number of new cases or deaths per 100,000 individuals in
that age group.
Furthermore, we calculated proportions of cancer as a cause of death in proportion to
other causes of death in the different age categories. Due to the privacy regulations
mentioned earlier, the provision of mortality data from Statistics Netherlands on the
individual level is restricted. Therefore, the proportions refer to the total population in
the age categories concerned, not only to the patients with cancer.
Table la The 10 most frequent cancer sites (ICD-9) in males according to age group in the Netherlands between 1989-1995: Absolute numben (N) and incidence rates
(Number/100,000 person-years)
Rank
1
2
3
4
5
6
7
8
9
10
55-64 jears
Site
Lung (162)
Colorectal
(153-154)
Prostate (185)
BUdder(188)
Stomach
(151)
Unknown
Pnmary(199)
Kidney(189)
Skin(P3)
Lymphoma
(200-202)
Larynx (161)
N Rate
12448 255.1
5593
4797
2230
2144
2076
1713
1680
1427
1315
114.6
98.3
45.7
43.9
42.5
35.1
34.4
29.2
26.9
65-74 years
Site
Lung(162)
Prostate
(185)
Colorectal
(153-154)
Bladder
(188)
Stomach
(151)
Skm(173)'
Unknown
Primary
(199)
Kidnev
(189) '
Lvmphoma
(200-202)
Pancreas
(157)
N
19940
Rate
566.9
14004 398.1
9019
4145
3689
3578
3300
2323
1906
1695
256.4
117.8
104.9
101.7
93.8
66.0
54.2
48.2
75-84 years
Site
Prostate
(185)
Lung(162)
Colorectal
(153-154)
Skin*(173)
Bladder
(188)
Stomach
(151)
Unknown
Primary
(199)
Kidney (189)
Lvmphocna
(200-202)
Pancreas
(157)
N
13212
12111
7087
3562
3265
2973
2323
1347
1201
1174
Rate
808.5
741.2
433.7
218.0
1998
181.9
142.2
82.4
73.5
71.8
85-94jears
Site
Prostate
(185)
CoJorectal (153-
154)
Lung(162)
Skin'(173)
Bladder(188)
Stomach
(151)
Unknown
Primary
(199)
Leukemia (204-
208)
Lymphocm
(200-202)
Pancreas (157)
N
3223
1545
1469
1352
808
712
528
300
262
237
Rate
938.4
4499
427.7
393.7
235.3
207.3
153.7
87.4
76.3
69.0
95*
Site
Skin'(173)
Prostate
(185)
Colorectal
(153-154)
Bladder<!88)
Stomach
(151)
Lung(162)
Unknown
Pnmary(199)
Lymphoma
(200-202)
Leukemia
(204-208)
Gallbladder
(156j
yean
N
94
82
48
36
22
18
13
11
10
5
Rate
570.9
498.0
291.5
218.6
133.6
1093
79.0
66.8
60.7
30.4
ICD: International Classification of Diseases
* Skin cancer other than melanoma and basaboma (mamlr squamous cell carcmoma)
i
Table Ik The 10 mott frequent cancer Met (ICD-9) in females according to age group in * e N « l y ^ ^ ^ ^ ^ , ^ ^ , 9 9 5 .
(Number/100,000 person-rears)
Rank
1
2
3
4
5
6
7
8
9
10
55-64 jears
Site
Breast(174)
Colorectal
(153-154)
Lung(162)
Utcrus(182)
Ovary(183)
Unknown
Primary
(199)
Melanoma
(172)
Kidncy(l89)
Lymphoma
(200 202)
Stomach
(151)
N
13724
4567
3234
2431
2053
1251
1066
992
990
853
Rate
270.5
90.0
63.7
47.9
40.5
24.7
21.0
195
195
16.8
65-74 years
Site
Breast(174)
Colorectal
(153-154)
Lung(162)
Uterus(182)
Ovary(183)
Unknown
Primary
(199)
Stomach
(151)
Lymphoma
200/202
Skin*(173)
Pancreas
(157)
N
14400
8088
3326
2833
2525
2049
1615
1604
1577
1450
Rate
325.1
182.6
75.1
63.9
57.0
46.3
36.5
36.2
35.6
32.7
75-84 year-
Site
Breast(174)
Colorectal
(153-154)
Unknown
Primary
(199) '
Stomach
(151)
Slrin'(173)
Uterus(182)
Ovary(183)
Lung(162)
Lymphoma
(200-202)
Pancreas (157
N —
i^ TT
87.4
2*10
22.9
21-.9
" 5
166
, 6 ,
'5-6
) 15-4
Rate
351.0
3028
84.4
78.1
75.3
66.5
58.2
58.0
53.7
52.9
85^
Sue
Colorectal
(153-154)
Breast(174)
Slbn'(173)
Unknown
Primary
(199)
Stomach
(151)
Pancreas
(157)
Lymphoma
(200-202)
Uterus(182)
Bladder
(188)
Ovary(183)
94 years
N
2950
2940
1504
944
903
537
530
497
464
384
Rate
321 1
320.0
63.7
102.8
98.3
58.5
57.7
54.1
50.5
41.8
')5"
Site
Skin'(173)
Breast(174)
Colorectal
(153-154)
Stomach
(151)
Unknown
Primary
(199)
Lymphomt(200/202)
Pancreas
(157)
Melanoma
(172)
Bladder
(188)
Gallbladder
(156)
years
N Rate
165 305.7
94
91
42
39
20
19
16
16
15
174.2
168.5
77.8
72.3
40.8
35.2
29.6
29.6
27.8
ICD: International Classification of Diseases
* Skin cancer other than melanoma and basalioma (mainly squamous cell carcinoma)
Results
Cancrr //TC/VAT/JCT -
During the 7-year study period (1989-1995), 335,156 incident cases of invasive cancer
were reported in Dutch people age > 55 years. A total of 2^,633 cases (8.2" o) occurred in
persons age >. 85 years and nearly 1000 (0.3%) were age 95* years. The annual incidence
rate for all cancer sites combined reached a peak at the age of 85 years ami decreased
thereafter (Fig. 1). In women ages 85-94 years, this rate was 1604/100,000; in men this
rate was nearly 3500/100,000.
Tables 1A and IB show the ten most frequent cancer sites in males and females
according to age category- in the registration years 1989-1995. In men (Table 1A),
prostate, lung and colorectal carcinoma were the three most frequent malignancies,
although in different ranking order. In the 95* years group, squamous cell skin cancer was
the most frequent whereas prosute carcinoma was the second, colorectal carcinoma the
thud, and lung carcinoma the sixth most frequent.
In women (Table IB) breast carcinoma was the most frequent malignancy in the 55-64
years, 65-74 years, and 75-84 years age groups, followed by colorecfld Ctfdnoma. In
women ages 85-94 years, colorectal carcinoma passed breast carcinoma with only a very
small difference. Squamous cell skin carcinoma climbed in rank with increasing age; in the
95' years group, this malignancy was the most frequent, whereas breast cancer was the
second and colorectal carcinoma the third most frequent. In the younger age groups (55-
64 years and 65-74 years) lung carcinoma was third most frequent, whereas in the older
age groups, lung carcinoma was not in the 'top ten'. We found that in the two oldest age
groups, unknown primary tumors ranked high, as fourth and fifth most frequent,
respectively. In addidbon, tumors of the pancreas and bladder appeared to be more
common in the oldest age groups, with incidence rates that were similar to, for example,
gynecologic malignancies in younger women (rates of between 30-60/100,000).
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Trends in age-specific cancer mortality rates from 1976-1995 (5-year periods) arc
presented in Figure 4 (4a: males; 4b: females). Cancer mortality rates in males decreased
or were stable below age 85 years, but increased by approximately 2()% in persons ages
85-94 years and by 50% in persons age 95' years. Female mortality rates were stable or
decreased slighdy, except in the 95* years age group, in which the rates showed an
increase in mortality until 1990 and then declined. Trends in age-specific rates of
individual cancer sites (Fig. 5a-i) showed that for several common cancer sites, mortality
rates were stable or decreased in the younger age groups, whereas they increased in the
oldest age groups. In men this was noted for prostate carcinoma (Fig. 5a) and lung
carcinoma (Fig. 5c), but not for colorectal carcinoma (Fig. 5b). In women this
phenomenon was noted for breast carcinoma (Fig. 5f) and ovarian carcinoma (Fig. 5g),
whereas for colorectal carcinoma (Fig. 5h) an increasing trend only was found in the age
95* years group.
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Figure 4a Trends in age-specific cancer mortality in males;
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Figure 4b Trends in age-specific cancer mortality in females;
data derived from Statistics Netherlands, 1976-1995
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For unknown primary rumors, an increasing trend in mortality rates m found in men
(Fig. 5d) and women (Fig. 5i) in all age groups, with the largest increase in the age groups
85-94 years and 95* years. In contrast, in all age groups, gastric carcinoma mortality rates
in men declined over the penod 1975-1995 and decbned most profoundly in the oldest
age groups (Fig. 5e).
Proportionally, cancer as a cause of death became less prominent with increasing age, at
shown in Figure 6. In the years 1991-1995, 42% of deaths in the total male population
ages 55-64 years were attributed to cancer, whereas this applied to 52".. of deaths in
women; these proportions in men and women were 11% and 7",,, respectively, in the 95*
years group. Approximately 40" •> of the very elderly died from cardiovascular diseases,
whereas pneumonia also was a common cause of death with proportions comparable to
those of cancer in the group of patients age 95' years. In approximately 1(1% of the very
elderly, the cause of death remained unknown because of incomplete description of the
symptoms or disease. Over rime (1976-1980 until 1990-1995) cancer as a cause of death
in proportion to all causes of death increased in all age categories, varying between 6% in
men ages 55-64 years to 0.3% in women age 95' years.
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Figure 6 Percentage of deaths by age category that were attributed to cancer in males
and females; data derived from Statistics Netherlands, 1976-1995
Discussion
Despite a clear proportional decrease with increasing age, cancer in the very elderly
population in the Netherlands (age 85* years) appears to be an important cause of
morbidity, with peak incidence rates for most common sites. In the period 1989-1995,
cancer was diagnosed annually in nearly 3% of Dutch men age .> 85 years and in nearly
1.5% of very elderly Dutch women. The pattern of age-specific incidence rates of all
cancers combined showed an increase with increasing age until ages 85-94 years,
whereafter ir declined. This applied to most of the common cancers in men and in
women, except for lung carcinoma in men in which incidence rates have started to
decrease in patients ages 75-84 years.
In a study conducted during the period 1988-1993 in California (USA)[8] colorectal
carcinoma was most common in women age 90' years, with breast carcinoma the second
most common malignancy. Skin cancer was not included in the analyses. In the current
study, breast carcinoma was the most common malignancy in women ages 55-84 years,
whereas colorectal carcinoma was the most common malingnancy in the group of
patients ages 85-94 years; the difference between the number of patients with colorectal
carcinoma and breast carcinoma was very small (10 cases). In both series, prostate
carcinoma was the most common in the very elderly men, followed by colorectal
carcinoma, whereas lung carcinoma was most common in men ages 55-75 years.
Various theoncs exist to explain the age-dependent increase in cancer incidence rates.
First, natural changes in the internal milieu or the organism (immune, endocrine, or
metabolic) are believed to provide increasingly favorable conditions for the malignant
trans forma Don or cells with increasing age |9,10|. Second, the age-related accumulation of
carcinogens might account for epithelial carcinoma induction as a turn turn of age in
sensitive individuals [11]. Third, decreased ability to repair DNA damage in older cells
may influence the process of neoplasnc transformation |I2], Fourth, oncogenic activation
or amplification might be increased in the older host, resulting in the increased initiation
or promotion or differential clonal evolution |13). Fifth, a decrease in immune
surveillance, or immunosencscence, might contribute to the increased incidence rate |13|.
These concepts were formulated mainly on the basis of studies showing sharp increases
in incidence rate with increasing age in persons ages 75' years or 85' years when
considered as a single caregory. However, we found that above the age of 85 years the
incidence rates of the most common cancers decreased. Without paying further attention
to the />nv W <wu of these theories, they all expect the rise in incidence rates to continue
with age, also above the age of 85 years, as we found for mortality rates.
Can the underreporting of cancer in the very elderly, because of less extensive diagnostic
workups, explain the deficit?| 14] In the current study population the percentage of
panents with histologically or cytologically confirmed diagnoses varied with age in males
as well as in females. In the age group 55-64 years these percentages were 98" « in males
and 97% in females, whereas in patients > 95 years these rates were 87% and 84%,
respectively.
Could this generation, born at the beginning of the 2O** century, have been less prone to
risk factors or had exposure to other risk factors than the younger generations? For
instance, changing smoking patterns have affected the incidence rate of lung carcinoma
between different birth cohorts (cohort effect). It has been suggested that natural
selection allows the less cancer-prone population to survive |13,15|. (ienctic resistance
against the many steps in pathogenesis may be accumulated over time. However, if the
latter were true, we would have expected to find decreasing mortality rates, as Smith
reported [15].
Mortality rates for common cancers in adulthood mostly were observed to increase
throughout the latter part of the life span, except for carcinomas of the lung and pancreas
in both genders and ovarian carcinoma in women, which declined in the very elderly age
groups.
To our knowledge there are very few published mortality data regarding cancer patients
beyond age ^ 85 years. Hadley [16] described an increase in age-specific mortality rates
from all cancers combined and from most individual cancers, except for lung carcinoma.
However, Smith [15] studied cancer mortality in very elderly people in the U.S. in 1990
and found decreasing mortality rates at age 90-94 years and ages 95-99 years for the major
cancer sites, except for breast carcinoma in women, which showed an increasing mortality
rate in women age > 100 years. At the current time, we are not able to provide a plausible
explanation for these different findings.
A clear increase in age-specific cancer mortality rates was observed in very elderly men
over the period 1976-1995, whereas in the younger age groups mortality rates declined.
The increase in mortality in men can be attributed largely to an increase in prostate
carcinoma and lung carcinoma deaths. In women age 95* years there was an increase in
mortality until 1990, which could be attributed largely to a rise in breast and ovarian
carcinomas. In both men and women, deaths from unknown primary tumors contributed
to the rise in mortality to a smaller extent.
Similar patterns of breast and ovarian carcinomas, comprising declining or stable
mortality rates in younger age patients and increasing rates in older age patients, have
been described previously 117-20), also in the Netherlands [21,22]. No upward trend in
cancer mortality was found in a worldwide study on cancer mortality in the elderly (65-84
years) [23). In fact, the pattern in elderly women was very favorable, because the lung
cancer carcinoma epidemic still was in its early phases in most countries and mere were
downward trends in gastric carcinoma and gynecologic carcinoma mortality, which are
particularly relevant. Researchers in Japan reported a rapid rise in cancer mortality in their
very elderly male population (1950-1990)[24). The authors suggested that a real increase
in cancer mortality may have occurred, although a tendency to perform more thorough
diagnostic workups in the very elderly also may have contributed to the increase.
Several phenomena might be responsible for the gradual increase in cancer mortality in
the very elderly. As mortality from cardiovascular diseases has decreased over the past
few decades (in the Netherlands from 416 in 1970 to 350 per 100,000 males in 1990) [25],
the probability of dying from other causes (e.g., cancer) has increased (compering causes).
The decrease in incidence rate of male lung carincoma (since 1980) and gastric carcinoma
(since 1950) may have had a similar effect. Part of the increase in prostate carcinoma
mortality mav be the result of an increase in exposure to risk factors, because major
causes ol prostate carcinoma still are unknown.
Several factors have been put forward to explain the increase in ovarian and breast
carcinoma in very elderly women. Changes in parity (decreasing number of live births
since the beginning of this century) between different birth cohorts of women could
explain some of the variation [17,20]. The widespread use of oral contraceptives also has
been suggested to be a contributing factor in the decline in ovarian carcinoma mortality
rates in the younger age groups (20). Improvement in treatment outcomes in general
without "real cure" (delayed mortality) and earlier diagnosis and more effective early
treatment in the young are other possible causes that have been put forward [16,21,26,27].
The completeness and reliability of recorded data also may affect trends over time,
especially in the very elderly [26,29]. For example, a study in Hiroshima compared the
diagnosis recorded on death certificates with those recorded at autopsy over a 28-year
period [29). Inaccuracy of death certificate diagnoses was greatest in the elderly, but there
was improvement in accuracy for many cancer sites over time. Similar circumstances may
explain in part the increase in mortality rates found in the current study.
Vic conclude that the highest incidence rates of major cancers were observed in the y
elderly population in the Netherlands. Age-specific mortality rates increased with age.
During the period 1976-1995 there was a rising trend in cancer mortality in the very
elderly. This was partly real and partly arnfacrual. Based on high incidence rates, cancer
mainly appears to affect the elderly. However, proportionally, «- 10° a of the ven elderly
die from cancer.
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General Discussion
Main findings
In this thesis, age-specific differences in diagnostics, treatment and survival were studied
for some common malignancies. It appeared that a substantial proportion of elderly
patients did not profit optimally from the available curative and palliative treatment
modalities. We found fewer diagnostic and staging procedures in the elderly and
significant differences in treatment between elderly and younger cancer patients. Elderly
cancer patients were more likely to receive no treatment or less intensive treatment.
Particularly large differences were found in treatment for lung cancer patients by age, with
high proportions of untreated patients among the elderly. Factors such as more
comorbidity or a low performance status could not sufficiendy explain these differences.
In patients with epithelial ovarian cancer, differences in treatment and survival were
found. In cervical cancer patients, survival differences by age were less clear. The study
on cancer incidence and cancer mortality among the very elderly population of the
Netherlands showed peak incidence rates for most common sites; incidence rates
increased with increasing age until the age of 85-94 years, whereafter they declined.
Mortality rates for common types of cancer increased throughout the latter part of the life
span, except for carcinoma of die lung, pancreas and ovary, which declined in the very
elderly age groups.
Methodological issues
Most of the data analysed in this thesis were provided by the Regional Cancer Registry
Maastricht, kept by the Comprehensive Cancer Centre Umburg (1KL). In order to
increase the power in two studies (Chapters 3 and 4) we received co-operation from the
cancer registries kept by the Comprehensive Cancer Centre South (IKZ) and the
Comprehensive Cancer Centre East (IKO). In the study on cancer in the very elderly,
data on the complete Dutch population were provided by the Netherlands Cancer
Registry (NCR) and Statistics Netherlands (Ch. 6).
In the two studies in which age-specific survival was addressed, we required information
on the vital status of the patients. Unfortunately, in the Netherlands, it is still a problem in
terms of time, money and privacy, to obtain complete follow-up data on cancer patients
for survival studies. Several sources need to be consulted, such as medical files, municipal
population registries, and the Bureau for Genealogy (CBG), the nation-wide registry of
deceased Dutch citizens. Currently, attempts arc being made to set up a regular link with
the national system of municipal population registries. When this has been realised, it will
be possible to calculate survival rates on a regular basis, in the same way as incidence and
mortality rates.
In an international context, cancer registries in the Netherlands collect a fairly extensive
data set, including clinical stage, pathological stage and initial treatment. Data on e.g. the
dose of cytotoxic drugs administered, the number of treatment cycles, or the dose of
radiotherapy and whether the treatment was stopped prematurely, are not included.
However, these are all items that may be relevant to the age-specific differences found in
the first study (Ch. 2) and in the rwo gynaecological studies (Chapters 3 and 4). Also, no
information is recorded about comorbidiry or performance status. These factors may help
to explain why a patient did not receive treatment or less intensive treatment. Therefore,
in the lung cancer study (Ch. 5) registration clerks collected addinonal information on
comorbidiry, performance status, treatment details and pulmonary function.
rir o/VAc (far*
A very important characteristic of the cancer registry system in the Netherlands ts the
very high quality of the data. Data from the registries of the 1KI. and I K / have been
included in the leading publication 'Cancer incidence in five continents' since 1992 |l-3).
Furthermore, several studies have been earned out which revealed high validity and
completeness of case ascertainment, also in the oldest age groups |4.5|. Above the age of
80 years, completeness was still 97" a. Validity is defined in (his thesis as the proportion of
cases in the registry with a given characteristic (e.g. cancer site, or agc| that truly do have
the characterisne |6). Completeness is defined as the degree to which all relevant cases art-
recorded. Also important is the completeness of the data in terms of trussing information
(the cases for which particular variables are unknown)|(>|. Results might IK biased when
certain groups, e.g. age groups, have higher proportions ot missing information on
specific items. In the studies presented in this thesis, the most striking item with high
unknown information proportions was stage at diagnosis in the elderly. I'urthcrmore,
patients with stage unknown often also had other variables missing, such as treatment
(Ch. 2], comorbidiry and performance status (Ch. 5). As stage unknown occurred more
often in the elderly than in the younger patients, the proportion of elderly patients for
whom patterns of care could be described was somewhat limited. In the population based
studies in this thesis, however, it was exactly their purpose to gain insight into the current
situation and draw attention to this unsatisfactory situation.
To record comorbidiry, methods introduced by the adjacent cancer registry kept by the
IKZ were used. This registry started to record comorbidiry in 1993 and has also carried
out a validation study [7]. Comorbidity is recorded by means of an adapted version of the
Charlson Comorbidity Index [8], which is well-defined and validated. Since 1999
comorbidiry has formed part of the standard registration item of the IKL for some
common malignancies (lung, oesophagus, head/neck, ovary and cervix).
Registration of performance status, which is an important prognostic factor especially for
lung cancer patients [9], is much more complicated. Performance status as such is not
well-documented and often missing from the medical files, except in patients treated in a
trial setting or at a radiotherapy department. Therefore, the registration clerks were
instructed to make notes on the condition of the patient based on the medical and
nursing reports. Then from those notes, a performance status was derived according to
the WHO scale which was first described by Zubrod et al [10). The idea to do it this way
stemmed from a study of Greenfield, who used nursing notes to define the performance
status of cancer patients [11).
Unfortunately, even after much effort, no performance status could be derived from the
medical files in 24% of the cases, with comparable proportions among all the age-groups.
In order not to lose information on too many patients, performance status unknown was
also included in the data analyses.
Treatment choice could not be explained by performance status, which is in agreement
with others [12]. However, comparison between studies may be difficult. Although scales
for performance status are well-validated (WHO, Zubrod, Karnofsky] it is not known
whether the method of collection is uniformly reliable. Furthermore it has been stated
that the application of the WHO score or the Karnofsky score to older cancer patients
can be problematic, because the degree of functional impairment may be underreported.
More precisely: 80% of the older patients scored 0 or 1 although more than 90% had
comorbidities and less than half were independent in ADL (activities of daily life) [13].
Therefore, the use of an ADL scale would probably had been more accurate and
informative. At present, it is quite impossible to retrieve this information retrospectively
from medical files.
77H?
Two studies in this thesis, addressed age-specific differences in survival (Chapters 3 and
4). In patients with epithelial ovarian cancer, age-specific differences in survival remained
valid even within the group of patients who had undergone surgery and chemotherapy,
which was the standard treatment for this type of cancer in that period. In contrast with
these findings, it was found that in a subgroup of cervical cancer patients, age was not an
independent factor after adjustment had been made for treatment. In both studies, the
effect of treatment on survival was considered to be the result of patient selection on
prognostic characteristics within the treatment groups, such as tumour volume (a larger
tumour meant a poorer prognosis), comorbidiry and performance status. This view was
based on the fact that in observational studies it is very difficult to estimate any real
differences in outcome between groups that received different treatment. This is because
the above-mentioned prognostic factors were not equally distributed over the groups [14],
and proper adjustment for these factors was not always possible due to a lack of detailed
documentation. For example, in the ovarian cancer patients treated with surgery and
chemotherapy, no information was available about the presence of residual disease after
surgery or about dosage reduction of chemotherapy. It is not so that only randomised
studies can provide reliable evaluations of treatment interventions (15). According to
McKce et al, randomised and non-randomised studies can provide complementary
evidence when prognostic factors are well understood, measured and controlled for. It is
important that clinicians who use this evidence are aware of the strengths and weaknesses
of each method.
Treatment options for elderly cancer patients
The studies in this thesis revealed reluctance to operate on ekfedy patients with
locoregional non-small cell lung cancer, breast cancer, advanced ovarian cancer and
cervical cancer. Surgery is still the main Treatment mixlaliry tor most solid tumours.
However, what constitutes "adequate" or 'appropriate' surgical therapy tor the elderly is
not always accurately known [16). We do noc know whether it should l>e any different
from the standard treatment provided to younger patients, because very few scientific
data on the older population are available from randomised trials. In the past, surgery has
been viewed to carry prohibitive risks for many elderly patients, but many recent studies
have indicated that surgical procedures can be performed safely in the elderly |16-IK|,
Apparently, careful preoperanvc assessment of the patient is 01 the main importance;
increased morbidity and mortality from surgery are associated with advanced stage disease
and emergency procedures [16). Older patients are more likely to be diagnosed with more
advanced stage disease, which was confirmed by the srudies in this thesis. Therefore, early
diagnosis and treatment in the elderly should be encouraged.
Radiotherapy plays an important role in the management of elderly cancer patient*. The
majority of elderly patients with locoregional non-small cell lung cancer received
radiotherapy with curanve intent (Ch. 5). This was also the case for elderly patients with
cervical cancer stage 1B-IIA (Ch. 4). In patients with non-Hodgkin lymphoma stage I, the
percentage of patients treated with radiotherapy also increased with increasing age.
Proportions of patients with advanced NSCIX that received radiotherapy for palliation
decreased with increasing age.
Radiotherapy is of particular benefit to older and frail cancer patients as an alternative to
surgery and systemic therapy. Existing data on the use of radiotherapy in elderly patients
indicate that this treatment modality can be applied to older people without increased
toxicity [19,20). Also, some investigators reported on the tolerance of cancer patients over
the age of 80 years to radiotherapy and the outcome [21). Side-effects were comparable
with those observed in younger patients. Oguchi ct al [22) even recommended
radiotherapy when applicable for patients aged over 90 years. However, the panents in
most of the studies had good performance status with little functional impairment and
were not representative of the general older population. A clear disadvantage of
radiotherapy especially for the older population is the long duration of therapy (alxiut 6-7
weeks for curative treatment and 2-4 weeks for palliative treatment) |21|. An American
study found that use of radiotherapy varied with the distance from the patient's home to
the radiotherapy department [23). Distances in the US, however, are not comparable with
those in the Netherlands. In a study on breast cancer patients in the Netherlands (IKZ),
the distance to the radiotherapy department per se was not found to affect the use of
radiotherapy [24J. In frail elderly patients with cancer, radiotherapy is the most widely
used treatment modality [21).
Compared to radiotherapy, the role of chemotherapy in the management of elderly cancer
patients was found to be small. The first study in this thesis (Ch. 2) showed that patients
aged over 70 years with ovarian or colorectal cancer or NHLwere less likely to receive
(adjuvant) chemotherapy.
Important studies have shown that age itself is not an absolute contraindication to
cytotoxic chemotherapy [25, 26). However, these studies are not considered to be
representative of the whole geriatric population, because older individuals were under-
represented, especially the very elderly (85* years). In addition, patients were selected on
the basis of an absence of severe comorbidity and good performance status. Furthermore,
many of the chemotherapy regimens used in these studies had lower dose intensity than
regimens in current use. Lymphoma studies that were specifically directed at older
patients presented different findings: firstly, older individuals seemed to be at increased
risk for myclotoxiciry, the most common complication of chemotherapy. Secondly,
hacmopoietic growth factors were found to be effective in older individuals and thus
enabled the administration of chemotherapy at full dosages. Studies on the treatment of
elderly patients with NHL have also been performed in the catchment area of the IKL
[27,28|. It was found that 26 out of 68 NHL patients aged 60 years and older were not
treated optimally (anthracycline containing chemotherapy, CHOP/CNOP) and that in 9
of them the reason was advanced age, despite good performance status [27].
Subsequently, attention was paid to the problem of elderly patients by physicians, and
regional protocols were designed in which the use of growth factor G-CSF in addition to
CI 1( )P was advocated. This resulted in more elderly patients being treated with the
standard chemotherapy regimens, without any major set-backs and with favourable
minvimiu
It is well-recognised that endocrine therapy plays an important role in breast cancer
patients especially in the elderly, because rheir rumours are often hormone responsive.
Tamoxifen is the most widely used endocrine therapy today and it also has the advantage
of virtually no-side effects |29|. This is reflected in the results described in Ch. 2: patients
of over 70 years with locally advanced breast cancer were more likely to receive adjuvant
endocrine therapy than adjuvant radiotherapy.
Cancer survival in the elderly
Poorer survival rates were observed in this thesis for elderly ovarian cancer patients and
for elderly cervical cancer patients with advanced stage. These results are in agreement
with other population-based studies, confirming a poorer prognosis for elderly patients
[3O-33J. In the King cancer study in this thesis (Ch. 5) it was not possible to earn- out a
survival analysis, because of incomplete follow up. Van Dijck et al. however, affiliated to
the cancer registry kept by the IK.O, studied treatment and survival in patients with non-
small cell lung cancer stage III A (n=212) diagnosed in 1989-1994 [34]. It was found that
the prognosis was poorer in patients who were older than 74 years, had at least one
comorbid disease, had not received treatment or who had lymph node metasrases.
Ktf
The Eurocare II project is paving particular attention to survival in the elderly, in order to
increase awareness of the need to develop better prevention and clinical management
strategies [35). Survival data on 701521 elderly European patients aged between 65 and ')*)
years and diagnosed between 1985 and 1989 were analysed. It was found that survival was
poorer in the elderly patients than in those aged berween 55 and 64 years for every site
(stomach, colon, rectum, pancreas, lung, larynx, melanoma, breast, ovary, utennc cervix,
uterine corpus, prostate, bladder, kidney, thyroid, NHL). It was also round that
differences berween older women and younger women were larger than those berween
older men and younger men. However, one must bear in mind that correction for stage
was not possible in these analyses, because Eiurocare does not have this information.
Age-related differences in survival in general are considered to stem from different
factors, including different diagnostic approaches and treatment of elderly cancer patients;
this is discussed in the next paragraph. It has also been argued that age-specific
differences in the biological behaviour of some rumours may be associated with a poorer
prognosis in older patients. This has been demonstrated for example in patients with
acute myelogenous leukaemia (AML), large cell non-Hodgkin lymphoma (NH1.) and
some forms of cancer of the ovary. In contrast, breast cancer and non small cell lung
cancer did show a more indolent disease in the majority of the elderly patients |36|.
Existing evidence for differences in tumour behaviour with age is, however, still limited
and controversial [37].
Factors that influence the choice of treatment in elderly cancer patientn
The studies described in chanters 2 to 4 showed that the drttrr and nature of the aire-
related differences in treatment varied according to rumour localisation. I'or example, large
age-specific differences were found in patients with lung cancer, while fairly small
differences were found in patients with colorectal cancer. The results of the lung cancer
saidy showed that even after adjusting for comorbidity and performance status, age was an
independent factor for not receiving treatment according to the guidelines (Ch. 5). This
strongly suggests that in lung cancer, calendar age forms the greatest argument to deviate
from standard treatment protocols. The question arises as to whether this is a typical finding
in lung cancer patients and whether other factors strengthen or weaken the influence of
calendar age. Other authors identified and categorised factors that influence the
management of elderly cancer patients: a) patient-related factors and b) physician or care
provider-related factors [36,38]. Examples of patient-related factors are physical and mental
status, age, social support and a patient's own preferences. Examples of care provider-
related factors are communication skills, care policies and preferences. Findings in the
studies in this thesis indicate that another category should IK* added: c) rumour-related
factors, including prognosis (type and stage of the tumour), treatment opportunities and
risks. In Table 1 all these factors are summarized, while the following paragraphs highlight
some of the factors that strengthen or affect the influence of calendar age separately or in
combination, and are most relevant to the results described in this thesis.
Table 1 Factor* that influence the choice of treatment in elderly cancer patients
Patient-related
Physician/care provider-related
Tumour-related
• physical and mental status
— comorbidiry
— performance/functional status
— nutritional level
• environment/background
— social network/family
— educational level
— financial situation
• patient's preferences, beliefs, ignorance
• calendar age
• knowledge/experience
• attitude/communication skills
• hospital policies
• care provider's preferences
• availability of care
• prognosis
— type of tumour
— stage
• treatment opportunities
— risks of treatment
— risks of withholding treatment
Firstly, it seems that physicians are most likely to deviate from the standard treatment
protocol if they have little hope that the treatment will be effective. Patients with lung cancer
have a very poor prognosis. Survival in patients with non-small cell lung carcinoma in the
Netherlands is only 15% [39). Recent improvements in survival by means of e.g.
chemotherapy are in the order of 4-6 weeks. Both patients and physicians hold pessimistic
views about the effectiveness of treatment and palliation. The reputation that chemotherapy
involves severe anil highly unpleasant side-effects still alarms many patients. It is likely that
this nihilism regarding treatment will lx- less intense when the results achieved by treatment
arc more promising. For example, the study on cervical cancer (Ch. 4) showed that the
majority of patients, including elderly patients, received standard treatment. However, in
contrast with lung cancer, the overall prognosis of cervical cancer was far better. 67% of the
patients were still alive after 5 years.
Secondly, it is conceivable that the decision of whether or not to apply standard treatment to
an elderly patient might depend on the nature and complexity of treatment. For certain
forms of cancer, e.g. breast cancer, there is a wide diversity of treatment combinations.
Several studies on breast cancer have shown that elderly patients receive less extensive
treatment or are treated less adequately than younger patients (24,40). We confirmed these
findings in our first study: 14" o of the elderly patients with stage I-III breast cancer and 59%
of the elderly patients with stage IV received endocrine therapy alone.
This single modality treatment was applied despite the fact that it has been known since the
fete nineteen eighties that Tamoxifen alone does nw constitute adequate treatment in early
stage breast cancer [41,42]. It is possible that physicians arc extra caunous in the case of
elderly patients, because they arc worried that certain forms ot" treatment might lie too
drastic for them. This may also apply to patients with ovanan cancer who receive extensive
abdominal surgery (debulking) that is essential to the run her course ot disease. In a study on
panents with stage III-IX' ovanan cancer, Ciershenson [43| found that more elderly women
had bulky residual disease after pnmarv debulking, possibly because the pnmarv debulking
operation had been less aggressive. Although post operative chemotherapy is standard
policy for ovarian cancer stages III-FV, in our study only 37" <• of patients aged 70 years and
older received this treatment combination, compared to 71" o of the panents of younger than
55 years and 54% of the patients aged 55-6") years. (Vie of the reasons may lx* that
chcmothcrapeutic treatments for cancer panents are still associated with significant toxiaty.
Currently, studies on chemotherapy regimens for older panents are Ix-ing performed to gain
more insight into toxiaty, survival and response rates in the elderly.
Risks of withholding a certain form of treatment might also play a role in decision-making.
For example, in the case of colorectal cancer, there is only one treatment: surgery. In a study
on 670 patients with colorectal cancer, Ciuagdagnoli did not find any differences in
treatment Ixrween the various age categories |44). Damhuis looked s|x*cifically .u resection
rates in patients with lung, stomach and colorectal cancer; differences per age category were
smallest for colorectal cancer (45). Thus, despite the fairly large operation risk (I 10"n),
surgery for colorectal cancer is still considered to he justified even in elderly patients,
possibly because if surgery is withheld, there is a considerable risk of intestinal obstruction.
In the study described in chapter 2 it was found that differences Ix'twcen age categories were
marginal for this form of cancer. In contrast, surgery was performed less often in elderly
patients with lung cancer, despite the rumour being operable. However, in the case of lung
cancer, radiotherapy is considered to be a good alternative for patients whose rumour is
smaller than 4 cm in size [46].
A fourth factor that might be of importance in the decision of whether or not to apply
standard treatment to elderly patients, lies on the side of the care providers. For example, a
Scottish population-based study on 1423 (early stage) lung cancer patients showed that being
referred to a lung specialist or being treated by a lung specialist had a significant influence on
the chance of receiving treatment with curative intent [47].
In the Netherlands, patients with head and neck cancer are treated centrally at university
hospitals. Treatments are protocolised and applied by a team of specialised health
professionals. It appeared diat there were hardly any age-specific differences in treatment in
these patients (see Ch. 2). This is worthy of note in view of the high prevalence of
comorbiditjes among patients with these alcohol and smoking-relatcd forms of cancer [7].
Characteristics of the hospitals themselves (e.g. size, teaching hospital, treatment policies)
might also affect decisions. In a population-based study using data from the Comprehensive
Cancer Centre South (IKZ), Post et al found substantial variation in treatment for prostate
cancer patients. More than twice as many patients diagnosed at larger hospitals underwent
radical prostatectomy than those diagnosed at smaller hospitals [48).
In a population-based study by the Comprehensive Cancer Centre East (IKO) on non-small
cell lung cancer patients stage IIIA, differences in resection rates were revealed between six
participating hospitals [34].
One of the main characteristics of ageing is the growing distinction between individuals,
physical and also social status, psychological and functional status. These factors
determine the biological age of a person and it is obvious that calendar age alone is not a
valid criterion for the choice of cancer treatment. Calendar age may be a starting-point for
decision-making regarding how to treat a particular patient, while successively taking into
account all other relevant factors. Only then can the decision to withhold or adapt
treatment be justified.
Geriatric assessment of elderly cancer patients
When deciding on the optimal treatment for elderly cancer patients, it has been
internationally recognised that the best guide can probably be obtained by making a
comprehensive multidimensional assessment of the patient. This assessment should
evaluate areas such as comorbidity, performance/functional status, emotional and
cognitive conditions, socio-economic conditions, nutrition and use of medication. It is
well-known that the number and seriousness of comorbid conditions, the degree of
functional dependence, cognitive deterioration and the presence of depression are related
to life-expectancy [13],
A comprehensive geriatric assessment with follow-up has proven useful in several
geriatric studies (49,50) and is considered as being useful in cancer patients for at least
four purposes (13,36):
1. to estimate a patient's life-expectancy;
2. to identify frail individuals who are at excessive risk;
3. to identify problems that may prevent the standard administration of chemotherapy
or radiotherapy (e.g. lack of social support or transportation);
4. to provide a common basis, i.e. a common language, in outcome research and quality
assurance.
The problem with making such a comprehensive assessment is that it will be time-
consuming and implementation will only be feasible at a few large cancer centres. Besides,
not all patients can or should undergo an extensive geriatric assessment. Balducci et al
recommended screening for all patients aged 70 years and older by means of a number of
questions to determine who should or should not undergo more extensive examination
before choosing (optimal) treatment (51). Based on these recommendations, we
composed a two-step assessment procedure (see Table 2). The first step comprises a
physical examination and specific questions to detect problems in physical, cognitive and
emotional functioning; the medical history provides information about the family
situation, medication use and comorbidities. When a problem is suspected in one of these
fields, step two consists of completing formal questionnaires to confirm or exclude the
problem.
With the informanon derived from this rwo-step assessment, estimates can be made of
the life-expectancy of a panent and of the tolerance and compliance to certain treatment
modalities, which together form the foundation for the diagnostic approach and the
therapeutic plan.
Table 2 Two-step gensttnc assessment ot" patients aged 70 years and older
Parameter
Finn «iep (screening)
Aaacasntent tool
Second step (confirmatory)
Physical functioning Physical examination
Set of 5 questions:
Cognitive/mental functioning
Emotional status
Comorbtdity
I'amily situation/social support
Paocnt's opinion and preferences
Medication use
Nutrition
Set of two questions:
• One question:
• Document number and type of
diseases
• Medical history
• Medical history
• Review number and type of
medication
• Calculate Body Mass Index, ask for
weight loss
• Formal ADI. (Activities for
Daily Ijving) test (e « Barthel
index |S2| or kat» male |S3|)
and I ADI. (lnsmunentitl
actixities lor DaiK Ijxitig teat
(eg Uwton scale |M|)
• Mini-Mental Status
l-.xarrun«ti(>n (I'olstem, I4H4
155])
• Geriatric Depression Scale
|56. S7|
• (irade tt<r nrrKumness
((.harlson index |H|)
• Diacust needn and »oltiiions
• l.ook for dupUcatlons,
interactions and compliance
• Mini Nutritional AJUOSMICMI
((iiiiKo? l')')7 |SK|)
/07
Recommendations and future research
-rice
Calendar age is a major barrier against adequate cancer treatment for the elderly.
However, to be able to evaluate the quality of treatment, particularly in relation with the
heterogeneity of the patient group, detailed data are needed, in the same way that data are
needed to adequately refer these patients for treatment. Assessments should not only include
comorbidity and performance status, but also cognitive status, nutritional level and social
and economic circumstances. The assessment tool described in the previous paragraph
could lx; used for this purpose. Based on such an assessment, the benefits of treatment, e.g.
prolonged survival, maintenance or improvement of quality of life and palliation of
symptoms, can be weighed against the risks of treatment, such as toxicity of chemotherapy
or complications after surgery.
C//n/ca/ researcA
It is of great importance to set up clinical research that does not exclude patients on the
basis of calendar age, comorbidity or performance status [59]. Over the past few years, there
has been an increase in trials that do not make age restrictions, or are specifically aimed at
elderly patients. Important factors that initially formed reasons to exclude them from
research (e.g. comorbidity and performance status) are now the very reasons why it is
important to study elderly individuals specifically. In these trials, quality of life should also
form an endpoint, because survival will not always be a suitable outcome variable owing to
the lower life expectancy of elderly patients. The representation of older patients in clinical
trials, however, is still very low [60], and often only relatively healthy patients are included.
Recruiting elderly patients for clinical research will require special attention in view of the
low general participation rate of patients in oncological studies [61,62].
Cancer re#/soy
In many of the above-described facets of oncological care (registration, evaluation, trial
participation), Comprehensive Cancer Centres can play a major role. Since the late 1980s
(and even longer (1^)) ™<-* "'"<•' regional cancer registries have been gathering a wealth of
information on the occurrence of cancer in the Dutch population, including tumour
characteristics, diagnostics and treatment methods. Besides bringing out reports on the
incidence of cancer and cancer mortality, population-based cancer registries in co-operation
with tumour working groups can serve various purposes, e.g. mapping diagnostics,
treatment and the course of disease after treatment (patterns of care), evaluating treatment
guidelines and consequently helpmg to optimise curative treatment and care for oncological
patients and to mould future-oriented health care policy.
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Appendices
Summary
At the end of the nineteen eighties and the beginning of the nineteen nineties, it was clear
that very little knowledge was available on the course of cancer in elderly people,
particularly on the specific treatment of elderly cancer patients. Existing data were mainly
based on patients of younger than 70 years. Clinical trials often employed an even lower
age limit. The scarcity of knowledge came to light because of increasing confrontation
with elderly cancer patients and their specific problems. Existing data show that 45% of
all cancer patients are 70 years or older at diagnosis. As this percentage can only be
expected to rise owing to the progressive aging of the Dutch population, cancer in the
elderly will attract increasing attention.
In this thesis, we look at age-specific differences in treatment and survival for various
forms of cancer. Furthermore, we describe cancer incidence and mortality rates in the
very elderly (85 years and older) in the Netherlands.
Chapter 2 describes a study on differences in diagnostics and treatment between younger
and older patients with several common forms of cancer. Data on patients aged 50 years
and older diagnosed in the period 1986-1992 with breast, colo-rectal, lung, ovarian, head
and neck cancer and non-Hodgkin lymphoma were supplied by the Comprehensive
Cancer Centre Limburg (n=6911).
In the patients with breast, lung and ovarian cancer, increasing age was associated with an
increase in the percentage of patients without histological confirmation (p<0.05). In lung
rumours, rhc percentage of cytological confirmations increased with age. The malignancy
grade according to the Working Formulation had been made in fewer elderly patients
with non-1 lodgkin lymphoma than in younger patients. In all the forms of cancer
addressed in this study, the percentage of patients who underwent extensive staging
investigations decreased with increasing age (c-factor). At all the forms of cancer
analysed, stage unknown at diagnosis was encountered more frequently in elderly patients
than in younger patients. All these findings support the hypothesis that diagnostics are far
less extensive in elderly patients than in younger patients.
Over I8"» of the total study population had not been treated. In the 50-59 year old
patients this was 7%, in the 60-69 year old patients 12% and in the 70 year and older
category this was 22%. The percentages differed per form of cancer and varied from 9%,
9% and 16% untreated with breast cancer, to 38%, 58% and 74% untreated with non-
small cell lung cancer per age category, respectively. Logistic regression analyses corrected
for stage and sex also showed that the chance of not receiving treatment increased with
age.
The vast majority of patients with breast cancer received treatment (99%). Elderly women
tended to receive one treatment modality alone, whereas younger women received a
combination of treatment modalities.
Chapter 3 not only addresses the influence of age on the choice of treatment in patients
with ovarian cancer, but also age-specific differences in survival. Treatment data and
information about vital status were analysed in 367 women with an epithelial form of
ovarian cancer diagnosed in the period 1986-1992.
Patients with ovarian cancer stage I-II (n=112) were treated with surgery (0-54 years:
51%, 55-69 years: 35% and 70 years and older: 48%) or with surgery followed by
chemotherapy (45%, 60% and 35% per age category, respectively). Two patients both
older than 70 years did not receive treatment. The majority of patients with ovarian
cancer stage I11-1Y (n=238) were treated with surgery + chemotherapy (the standard
treatment), but the rates decreased with increasing age (71%, 54% and 37% per age
category, respectively). A larger proportion of the elderly population received
chemotherapy alone (22%, 28% and 37% per age category) or did not receive treatment
(2%, 13% and 21% per age category).
In order to correct for death from compenng causes, relative survival rates were
calculated. Relative five year survival rates were 54" o, 34" <> and 17" o in the age categories
0-54 years, 55-69 years and 70 years and older, rcspecnvcly. In panents with stage 1-11 at
diagnosis, these rates were 86%, 66% and 51%. while in panents with stage 111 IV these
rates were 33%, 20° o and 5% per age category'. Liven when the analyses were confined to
panents who received surgery + chemotherapy (the standard treatment) the age effect
remained.
Chapter 4 describes a similar study on cervical cancer, which generally has a Iwtter
prognosis than ovanan cancer. The standard treatment for early stage cervical cancer was
surgery; for more advanced stages, standard treatment comprised surgery followed by
radiotherapy, or radiotherapy alone. In inoperable panents with early stage cancer,
radiotherapy was also an accepted alternative.
The study was performed on data on 1176 panenis who were diagnosed with cervical
cancer in the period 1986-1996. Study follow-up ended on 1 January 1998.
Only 5% of the patients aged 70 years and older (n=224) were diagnosed with an early
stage (1A). This percentage was 30% in panents of younger than 50 years (n=612) and
11% in the panents aged 50-69 years (n=340). Over 48% of the 70' age category patients
with stage 1B-IIA were treated with radiotherapy as the only treatment modality (<50
years: 8%; 50-69 years: 25%). The majority of panents with an advanced stage received
radiotherapy alone: 70' years: 76%, 50-69 years: 86%; < 50 years: 72%. Over 10% of the
70* age category patients did not receive curanve treatment (50-69 years: 5%; <50 years:
1.5%).
Five year relative survival in the total patient population was 69% (95% BI: 66%-72%)
and differed per age category (<50 years: 81%; 50-69 years: 57%; 70' years: 49%) and per
stage (FIGO stage I A: 97%; IB-IIA: 78%; IIB-IVA: 37%; and IVB: 14%).
Mulnvariate analyses on patients with stage 1B-IVA who were treated with surgery,
radiotherapy or both were performed to investigate the independent influence of age on
relative survival. In this group of panents, stage and treatment rather than age were the
most important prognostic factors. However, it is very probable that the influence of
treatment was caused by the selection of patients for treatment on the basis of other
factors, such as rumour size, comorbidity and performance sums.
In the three studies described above, we did not include any information about
accompanying diseases (comorbidity) or performance status (the general physical
condition) of the patients. Both these factors might play a role in the choice of treatment.
To perform the study described in Chapter 5, this information together with extensive
data on treatment and pulmonary function were gathered by registration clerks from the
IKL and IKO.
The study population comprised 803 patients diagnosed with non-small cell lung cancer
in the period 1997-1998; 51% of the patients were 60-74 years of age and 27% were 75
years or older. After correcting for stage at diagnosis, analyses showed that the percentage
of patients who were not treated according to the guideline increased with increasing age.
Significant associations with comorbidity and performance status were only found in the
patients with early stage disease. In stage IV patients, poor pulmonary function was
associated with not receiving palliative treatment. Calendar age was found to be of
decisive importance in the choice of treatment for patients with non-small cell lung
cancer.
Chapter 6 analysed the incidence of mortality from cancer at a very advanced age (85*
years). Due to aging of the population, this age group has steadily been increasing in si2e.
In 1976, approximately 99,000 persons in the Netherlands were 85 years or older; in
1995, this number had increased to 203,000.
At present, the majority of cancer registries calculate incidence rates for the total group of
85' , sometimes even for 65 *. The increased number of very elderly people has made it
possible and much more relevant to distinguish between several age categories above the
age of 85 years. In this study, we analysed the age categories 85-94 years and 95 years and
older. Incidence data on all patients of 55 years and older in the Netherlands who were
diagnosed in the period between 1989-1995 were made available by the Netherlands
Cancer Registry (NKR). Population rates and causes of death were supplied by Statistics
Netherlands (CBS).
In the period 1989-1995, a total of 27,633 persons aged 85 years and older were
diagnosed with cancer. This was over 8% of the total number of patients (335,156). For
all forms of cancer together, the age specific incidence reached a peak at the age of 85-94
years, after which it decreased. For lung cancer, the peak was reached as early as at the age
of 75-84 years.
For nearly all the forms of cancer studied, mortality from cancer increased with increasing
age. 'I "his did not apply to lung and pancreatic cancer in men and women, or to ovarian
cancer in women.
The proportional mortality from cancer appeared to decrease with increasing age: in men
anil women aged 55-64 years, 42% and 52% died of cancer, whereas in men and women
of older than 95 years, these rates were 11% and 7%, respectively.
Various explanations can be put forward for the finding that instead of increasing, the
incidence decreased with advancing age. For example, under-reporting of cancer may
have occurred in the very elderly liecause less extensive diagnosnes were employed.
However, this percentage cannot be all that large. The fact that the diagnosis was not
confirmed microscopically as often in elderly patients leads to the assumption that
although the diagnostic procedure was less extensive, a clinical diagnosis had been made.
A second possible explanation is that the very elderly had experienced less exposure to
certain carcinogenic substances, e.g. because smoking had not yet become a general habit
(cohort effect). It has also been suggested that the very elderly are less likely to develop
cancer because they have strong genes that break down carcinogenic substances in the
body.
This thesis is concluded with a general discussion in which the most important tindings
are summarized and elaborated on, based on current developments in the field of cancer
in the elderly.
Over the past few years, increasing attention has been paid to the treatment of elderly
cancer patients, both to surgical treatment and to radiotherapy and chemotherapy.
Doctors and other health professionals agree in principle that even in patients of
advanced age, these forms of treatment have a great deal to offer cither with curative or
palliative intent.
In addition, we postulate that the influence of calendar age on the choice of treatment
partly is determined by the prognosis of the form of cancer in question, the nature and
complexity of the treatment, possible risks of withholding treatment and by the attitude*
and preferences of the treatment team.
A treatment approach according to protocol that has been tried, tested and approved in
younger adults, may not be suitable for elderly patients without further consideration)!
being made. One of the major characteristics of growing old is that people age at different
rates, so there can be vast differences between elderly people. Therefore, age in itself, i.e.
calendar age, is not a suitable criterion on which to select patients for a certain treatment.
The differences between elderly people can l>c physical, social, psychological and
functional; these aspects determine the biological age. This notion has led internationally
to the insight that extensive genatnc assessment (Comprehensive (icnatnc Assessment
CGA), which is already being used for other disorders in the genatnc population, can
probably make a positive contribution to the correct management of elderly cancer
patients.
A treatment that deviates from the standard treatment or deviates from the guideline is
not automatically an inferior treatment. When this treatment choice has been made after
careful consideration of the different factors, then adaption of the treatment seems
justified.
At the end of Chapter 7 a number of recommendations are made for further research and
for clinical practice. For example, we argue in favour of introducing an extensive or less
extensive genatnc assessment for elderly cancer patients to measure physical, cognitive
and emotional functioning, comorbidity, nutritional level, family situation, personal
preferences and medication use. It is also important to carefully document all the data so
that evaluations can be made of the treatment applied. In the same way we argue in
favour of setting up trials for elderly patients that also include cases with comorbidiry or a
poor performance status and to stimulate the participation of elderly patients in trials.
Last but not least, attention is paid to the supporting role that the Comprehensive Cancer
Centres can play in these processes.
S a m e n v a t t i n g
Eind jaren 80, begin jaren 90 van de vorige eeuw werd het duidelijk dat kennis over het
verloop van kanker bij ouderen, maar vooral ook kennis over de specifieke behandeling
van oudere kankerparienten nauwelijks voorhanden is. De aanwezige kennis over
behandelingsmethoden is veelal gebaseerd op parienten jonger dan zevenrig jaar. Bij
klinisch onderzoek wordt namelijk vaak deze of een nog lagere leeftijdsgrens
aangehouden. De schaarste aan kennis komt aan het lichr omdat men in toenemende
mate geconfronteerd wordt met oudere kankerparienten en hun specifieke problemariek.
Immcrs, 45% van alle kankerparienten is bij diagnose 70 jaar of ouder. Omdat dit
percentage allcen nog maar kan toenemen gezien de voortschrijdende vergrijzing van de
Nederlandse samenlcving, komt /ferf»/fe<r />// <j/w/rn»» steeds meer in de belangstelling te staan.
In dit proefschrift wordt voor verschillende vormen van kanker gekeken naar
leeftijdspecificke verschillen in behandeling en overleving. Daarnaast wordt het
voorkomen van en de sterfte aan kanker onder de oudste ouderen (85 jaar en ouder) van
Nederland beschreven.
In hoofdstuk 2 wordt het onderzoek naar verschillen in diagnosriek en behandeling
tussen jongere en oudere kankerparienten voor enkele veel voorkomende vormen van
kanker beschreven. Gegevcns van parienten in de leefrijd van 50 jaar en ouder,
gediagnosriceerd in de periode 1986-1992 met borst-, dikke darm/endeldarm-, long-,
eierstok- en hoofdhalskanker en het non-Hodgkin lymfoom werden verstrekt door de
kankcrregistrarie van het Integraal Kankercentrum Iimburg (N=6911).
Wat bctreft diagnosriek werd bij parienten met borst-, long- en eierstokkanker met het
srijgen van de leefrijd een duidelijke toename van het percentage parienten zonder
histologische bevesriging gesignaleerd (p<0.05). Bij longrumoren nam het percentage
cytologische bevesriging toe met de leefrijd. Voor het non-Hodgkin lymfoom gold dat de
maligniteitsgraad volgens de Working Formulation vaker niet geclassificeerd was bij
oiideren dan bij jongercn. Bij alle besnideerde vormen van kanker stecg het percentage
parienten waarbij minder uitgebreid stadicringsonderzoek had plaatsgevonden met de
lccftijd (c-factor). Voor alle bestudcerde vormen van kanker werd gevonden dat het
stadium waarin de ziekte zich bevond bij diagnose vaker onbekend was bij ouderen dan
bij jongeren. Al deze bevindingen ondersteunen de hypothese dat ouderen minder
intensief werden gediagnosriceerd dan jongeren.
Ruim 18% van de gehele ondcrzoekspopulatie werd niet behandeld. Van de 50-59 jarigen
was dit 7".., van dc 60-69 jangen 12% en van de parienten 70 jaar en ouder 22%. De
percentages verschildcn echtcr nogal per vorm van kanker, varierend van respecrievelijk
9%, 9% en 16% niet-behandelde parienten per lcefrijdscategorie bij borstkankcr tot 38%,
58% en 74% niet-behandelde patienten met ccn nict-klcinccllig longcarcinoom. Ook uit
de de logisrischc regrcssie bleek dat, gecorrigeerd voor stadium en geslacht, de kans om
niet te worden behandeld tocnam met de lccftijd.
Patictm-n met borstkanker werden bijna allemaal behandeld (99%), oudere vrouwen
kregen echter vaker allcen hormonale thcrapie, terwijl jongere vrouwen werden behandeld
met een combinarie van behandelingsmodaliteiten.
In hoofdsnik 3 wordt met allccn dc invloed van leefnjd op dc kcuzc van bchandcling
voor pancnten met eiemokkanker nader bekeken, maar worden ook lecfnidspecificke
verschillen in overlevwg besrudeerd. \'an 367 vrouwen met ccn epuhchale vorm van
eierstokkanker, gediagnosnceerd in de penodc 1986-1992 wcrden belundchngsgegcvcns
en informaae over de vitale status geanalysccrd.
Panenten met eierstokkanker stadium I-II (n=l 12) wcrden bchandeld met chirurgie (0-54
jaar 51%, 55-69 jaar 35% en 7() jaar en ouder 48%) of met clunirgic gevolgd d(H>r
chemothcrapie (45%, 60% en 35% per lecfnidsgroep). Twee panenten, l>eiden ouder dan
70 jaar werden nict bchandeld. Paaenten niet cierstokkanker stadium 111-IN" (n=238)
werden grotcndcels behandeld met chirurgic+chcmotherapie (de standaardlM-handcling),
maar dit percentage daalde naarmate de lectnjd stocg ("*!%, 54" o en 37% per
leefnjdsgrocp). Oudcrcn werden vakcr bchandeld met chemotherapie alleen (22" o, 28%,
37% per leefnjdsgrocp) en wcrden ook vakcr nict bchandeld (2%, 13% en 21% per
lecfnjdsgroep).
Tcneinde te corngcren voor de "normalc" stcrftckans wcrden rclatievc ovcrlcvingscijfcrs
Ix-rekcnd. De relancvc vijrjaarsovcrleving bedroeg rcspecnevclijk 54%, 34" o en 17% voor
de leefnjdsgroepen 0-54 jaar, 55-69 jaar en 70 jaar en ouder. Voor paticnten met stadium
III bij diagnose waren dczc percentages respccncvclijk 86%, 66% en 51"n en voor
panenten met stadium III-IV 33%, 20% en 5% per lecfnjdsgrocp. Ook wannecr lourcr
panenten behandeld met chirurgie+chemotherapie (dc srandaardhchandcling) in dc
analyse werden opgenomen blcef het effect van leefnjd bestman.
In h(H)fdsruk 4 wordt een vergelijkbare srudie heschreven, maar dan voor
baatmoederhalskanker, ecn vorm van kanker met een over het algcmeen InMcrc prognosc
dan ciersrokkanker. Standaardbchandcling voor baarmoederhalskanker in een vrocg
stadium is chirurgic en in ccn verdcr gevorderd stadium chinirgic grvolgd door
radiotherapie of radiothcrapie alleen. Voor panenten die met gcopcrccrd kunncn worden
is radiotherapie ook in ecn vroeg stadium een geaccepteerd alternarief.
De studie was gebaseerd op de gegevens van 1176 parientcn bij wic ccn invasief
cervixcarcinoom was vastgesteld in de pcriode 1986-1996. Kinddatum van follow-up was
1 januari 1998.
Slechts 5% van de patienten van 70 jaar en ouder (n=224) werd gcdiagnosriccerd met ccn
vroeg stadium (IA). Dit percentage was 30% bij de vrouwen jonger dan 50 jaar (n=612)
en 11% bij vrouwen in de lecfnjdsgroep 50-69 jaar (n=34O). Ruim 48% van dc 70*
parienten met een stadium IB-IIA werd bchandeld met radiothcrapic als enige
behandelingsvorm (< 50 jaar: 8%; 50-69 jaar: 25%). De mecstc parienten met ecu
gevorderd stadium (IIB >) werden behandeld met alleen radiotherapie: 70' jaar: 76%, 50-
69 jaar: 86%; < 50 jaar: 72%. Ruim 10% van de 70' vrouwen werd niet curaricf
behandeld (50-69 jaar: 5%; < 50 jaar: 1,5%).
De vijf-jaars relarieve ovcrleving van de gehelc parientenpopularie was 69% (95% BI:
66%-72%) en verschilde per leefrijdsgroep (<50 jaar: 81%; 50-69 jaar: 57%; 70' jaar:
49%) en per stadium (FIGO-stadium IA: 97%; IB-IIA: 78%; IIB-IVA: 37%; IVB: 14%).
Middels mulrivanate rcgressie werd voor parienten met ecn stadium IB-IV'A, bchandcld
met chirurgie, radiotherapic of beiden, gekeken naar de onafhankclijkc invloed van lecftijd
op de relarieve overleving. Het bleek dat voor dezc groep parientcn met lecftijd maar
stadium en behandeling dc belangrijkste prognosrische factoren warcn.
Het is hierbij zecr waarschijnlijk dat de invloed van de behandeling in feite werd
veroorzaakt door een selectie van paaenten voor behandeling op basis van anderc
factoren zoals tumorgroorte, co-morbiditeit en performance stanis.
In de drie voorgaande studies hadden we geen informatie over bijkomende ziekten (co-
morbiditeit) en over de performance status (de algemene fysieke conditie) van patienten.
Dit zijn beide factoren die mcdc de behandelingskeuze kunnen bepalen. Voor de studie
beschreven in hoofdsruk 5 werd deze informatie tezamen met uitgebreide
behandclingsgcgevens en de longfunctie door de registratiemedewerkers van het IKL en
IKO vcrzameld. Het betrof 803 patienten gediagnosticeerd met niet-kleincellig
longkanker in de periodc 1997-1998. Van deze patienten was 51% in de leefrijd van 60-74
jaar en 27% was 75 jaar of ouder. Het bleek dat, rekening houdend met het stadium bij
diagnose, het percentage patienten dat niet behandeld werd volgens de richtlijn toenam
met dc leeftijd. Alleen bij de vroege stadia werd een verband met aanwezige co-
morbiditcit en performance status gevonden. Bij stadium IV patienten werd een verband
gcvonden tussen een slechte longfunctie en het niet onrvangen van palliatieve
behandeling. Kalenderleeftijd bleek van doorslaggevende betekenis te zijn bij de
therapiekeuze voor patienten met een niet-kleincellige longtumor.
In Hoofdsruk 6 wordt de incidentie van en sterfte aan kanker op zeer hoge leeftijd (85*)
beschreven. Door de vergrijzing van de bevolking neemt deze leeftijdsgroep sterk toe in
aantal. Warcn cr in 1976 99.000 personen in Nederland 85 jaar of ouder, in 1995 was dit
aantal gestegen tot 203.000.
Tot nu toe berekenen dc meeste kankerregistraties incidentiecijfers voor de totale groep
van 85-plussers, soms zelfs voor 65*. Het toegenomen aantal oudste ouderen maakt het
center mogelijk en relevanter ook boven dc lecfajd van 85 jaar meerdere leeftijdsgroepen
te ondcrschciden. Voor onderhavige studie waren dit de categorieen 85-94 jaar en 95 jaar
en ouder. Incidentie gegevens van alle patienten van 55 jaar en ouder in Nederland,
gediagnosticeerd in dc periodc 1989-1995 werden ter beschikking gesteld door de
Nedcrlands Kankcrrcgistratic (NKR). Bevolkingsaantallen en doodsoorzaken werden
vcrstrckt door het C.cntraal Bureau voor de Statistiek.
In totaal werd in de periodc 1989-1995 bij 27.633 personen van 85 jaar en ouder kanker
gcdiagnosticecrd. Dit was ruim 8% van het totale aantal patienten (335.156). Voor alle
vormen van kanker samen berciktc de leeftijdspecifieke incidenrie een piek op de leeftijd
van 85 94 jaar waarna de incidentie weer daalde. Voor longkanker werd de piek al bereikt
bij patienten van 75 84 jaar.
Voor bijna alle bestudeerde vormen van kanker steeg de sterfte aan kanker met het stijgen
van de leeftijd. Dit gold niet voor long- en alvleesklicrkanker bij mannen en vrouwen en
met voor eierstokkanker bij vrouwen.
De proportionclc sterftc aan kanker bleek bij het ouder worden af te nemen: bij mannen
en vrouwen van 55-64 jaar sricrf 42% en 52" o aan kanker, maar bij mannen en vrouwen
ouder dan 95 jaar waren deze percentages respecdevelijk 11% en 7%.
Vcrschillende verklaringen worden aangedragen voor de bevinding dat de incidentie in
plaats van tc blijven srijgen, op hoge leeftijd weer daalde. Zo zou er sprake kunnen zijn
van een onderrapportage van kanker bij de oudste ouderen doordat minder diagnosbek
wordt vcrricht. Dit percentage kan echtcr nooit heel groot zijn.
Het feit dat de diagnose bij ouderen minder vaak microscopisch bevesngd is. doet
vermoeden dar ofschoon minder uitgebreid, dc klmische diagnose wel gesreld wordt. lien
tweede mogelijke verklanng is dat de oudstc ouderen minder blootgesteld /ijn aan
bepaalde kankerverwekkende stoffen, bijvoorbeeld omdat roken nog geen algcmcen
gebruik was (cohoneffect). Ook wordt wel gesuggereerd dat oudste ouderen minder vaak
kanker onrwikkelen doordat zij beschikken over sterke genen om kankcrvcnvckkcndc
sroffen in het lichaam af te breken.
Met proefschrirt wordt afgesloten met een algemcne discussie waann de hclangnjkstc
bcvindingen worden samengevat en toegehcht aan de hand van luudigt* onrwikkehngen
op gebied van kanker bij ouderen.
Zowel bij de chimrgische behandeling van kanker als voor de nidiothcrapic cn
chemotherapie wordt de laatste jaren een toegenomen aandacht v<x>r de Ix'haiulclmg van
dc oudere kankerpanent geconstateerd. Ansen en andere Ix-handclaars zijn het er in
pnncipe over ecus dat ook op oudere lecrnjd dcze behandelingsvonnen hctzi| curarict,
hetzij pallianef, veel te bieden kunncn hebben.
Daamaast wordt betoogd dat de tnvloed van de kalenderlecfnjd op de helundelingskeuze
mede bepaald wordt door de prognosc van de Ix'trertcndc vorm van kanker. de aard cn
gecompliccerdheid van dc behandeling, evenrucle nsico's van het nalatcn van een
behandeling en door de houding en v(K)rkeuren van dc brhandelaars.
Een prorocoUaire aanpak zoals die bi) |ongcrc volwasscnen gclmukcli|k en heproefd is, is
met zonder mecr geschikt voor ouderen. Een van dc bclanghjkstc kenmerken van hct
ouder worden is namclijk dat mensen ondcrling meer gaan verschillcn. Daarom is Iceftijd
op zich, de 'kalender-leefnjd gcen geschikt cntcnum om mensen tc selccteren voor een
bepaalde behandeling. De vcrschillen russcn de oudcr wordendc mensen die met alleen
hchamelijk, maar ook sociaal, psychisch cn functioned kunncn zijn hcpalcn de
biologische lecfn|d. Dit besef heet't intcrnationaal geleid tot het in/icht dat ecu uitgelireidc
gcriatrische beoordeling (Comprehensive Cicriatric Assessment CCiA) zoals reeds
gebruikt bij andere zicktcbceldcn in de gcriatrische popularic, wcllicht een positievc
bijdrage kan levcren aan het op juistc wijze bchandclen van dc oudere kankcrpaticnt.
Een behandeling die afwijkt van de standaard, of nict bchandelcn volgcns de nchtlijn,
betekent niet automatisch een inferieure behandeling. Wanncer dcze bchandclingskcuzc
tot stand komt na zorgvuldigc afweging van dc vcrschillcndc factorcn, lijkt een aanpassmg
van de behandeling gerechrvaardigd.
Aan het eind van hoofdsruk 7 wordt een aantal aanbevelingen gcdaan vtxir vcrder
ondcrzoek en voor dc klinische prakrijk. Onder meer wordt gcplcit voor dc invoenng van
een meer of minder uitgebreide geriarrische bcwirdeling van oudere kankcrpatientcn op
gebied van fysiek, cognirief en cmorioneel funcnoncrcn, co-morbidircit,
voedingstoestand, gezinssiruarie, eigen wensen en mcdicijngcbruik. Ik-langrijk hicrbij is
zorgvuldige documentane van de gegevens, zodat cvaluahc van dc gegeven Ix-handcling
kan plaats\indcn. liveneens wordt geplcit voor hct opzetten van trials voor oudere
paricnten, ook voor hen met co-morbiditeit of een slechte performance status cn voor hct
stimuleren van deelname van oudere patienten aan trials. Tenslottc wordt aandacht
geschonken aan de ondersteunende rol die de Intcgralc Kankcrccntra hicrbij kunnen
spclen.
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Dankwoord ,u
Op hct moment dat ik in 1995 bij hct Integraal Kankerccntrum Iimburg (IKL) aan mijn
stageonderzoek begort, had ik nooit kunncn denken dat hct resultaat van deze stage ooit
nog eens een hoofdsruk van rrujn proefschritt zou beslaan. Mijn hegelciders van tiwn
hebben ook bij hct uitcindch)kc emdproduct. dit proctschnit. dc ml van bcgclciding op
zich genomen, Pict van den Brandt als promotor, Leo Schouten en Harry Schoutcn
bciden als co-promotor. Het vcrhaal over het samcnvallcn van mijn telefoontje voor cm
mogebjke stagcplaats en dc wens van l>eo voor een suguir op dc atdclmg
Kankerregistrane en Epidcmiologic is al een bcerje legendansch aan het worden. Hij had
met Pict van den Brandt, toen epiderruologisch consilient van hct IKI, hct idee opgevat
dat kanker bij oudcren' best eens interessant onder/oek kon opleveren. We ujn djuir
samen mec aan de slag gcgaan en van het een kwam het ander
Leo, het zijn seven jaren van intensievc, minder intensicve maar vooral prettigc
samcnwerlung gewcest, waarbij jou stimulercndc houding voor mij erg bclangnjk was. Je
liet mij zeer zelfstandig werken, maar was cr wcl altijd als ik met vragen ot prohlnncn /at.
Jc hebt voor mij gclobbied bij directcurcn voor vcrlcnging van mi|n jaarenntracten en wat
waren we blij toen Sjoerd Adema mij in 1998 dc mogebjkhcid IKMKI mijn ondcrzoek at" tc
ronden in de vorm van een promorie. l.co, bedankt voor allcs!
Piet, vanaf het begin ben jij bij de totstandkoming van dit proefschnt't betrokken gewecst.
al was het dan meer op afstand. Jc was een rots in de branding op dc achtcrgrond.
Bedankt voor jc knnsche bilk, je stabiliteit en jc vcrtrouwen.
Harry, ook voor jou gcldt dat jc vanaf hct Ix-gin bij dit proefschrift In-trnkkcn IHIII
geweest. Verrasscnd maar niet vcrvelcnd vond ik altijd jou dircctc manicr van
communiccren. Zonder <x>k maar een woord teveel zeg of schrijf jc wat jc van icts vindi.
)ammcr dat het met onzc curegionalc vrienden (nog) op nicts is uitgclopcn.
Ja, en dan natuurlijk nog al die anderen Mijn dank gaat uit naar allc collega's
van het IKL, bedankt voor jullic belangstelling en stcun op allcrlci gcbied. Speciaal wil ik
enkele registratiemedewerkers noemen die nauw betrokken zijn gewcest bij hct
longproject: Jose Heijnen, Marjon Groven, Corry Strijbos en oud-medewerkcrs Beppy
Dols, Annelies Willemars en Rene Spruit (de laatste nu werkzaam op dc afdeling
automatisering). Het 'longproject' heeft jullic heel wat hoofdbrckens en vooral tijd
gekost, zonder jullic had ik echt niets kunnen beginnen. Ook de registranemedewerkers
van het IKO kunnen hierover meespreken! Johan Bruijncn, samen hebben we hct een
rijdje zonder afdclingshoofd mocten docn en dat ging hartstikkc gocd! I let was prettig jou
als kamergenoot te hebben. Hans Huvenccrs, je staat hicr in het rijtje (cx)collcga's, maar
je was natuurlijk veel meer dan een collega. Ik mis onze wandelpauzes langs de Maas nog
steeds!
Verder verdienen alle leden van de verschillcnde projectgroepen vcrmelding. Jos van
Dijck en Adri Voogd wil ik bedanken voor hun kritische blik vanuit epidemiologisch en
registratie- oogpunt. Alle consulenten en leden van tumorwerkgroepen die bctrokken
waren bij de verschillende projecten wil ik van harte bedanken voor de prettigc
samenwerking.
De leden van de beoordelingscommissie ben ik erkentelijk voor het lezen en beoordelen
(soms zelfs in de vakantie) van dit proefschrift.
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Mijn familieleden en vrienden (onder wie veel ex-collega's, het 'spattend buikje' en de
leesgroep) wil ik heel erg bedanken voor nun niet aflatende interesse en medeleven in
mijn persoontje! •., >,-; «.-, . . , , ; „ .
Ria Baaijens-de Rijke (zusje van me) en Wilbert (Willy van de Inkom) Joosten wil ik
bedanken dat zij mijn pararumfen willen zijn. Ik weet het Rietje, het is dan wel geen
bosnimf maar toch... j
Mijn vader en moeder, vanaf het moment dat ik zeer eigenwijs naar de 'grote school'
wilde hcbbcn jullie mij alle ruimte gegeven en altijd opengestaan voor mijn keuzes en dit
heeft jullie heel wat slapeloze nachten bezorgd; bedankt voor jullie grenzeloze liefde!
Ueve Ralf, het cnigc war ik tegen jou kan zeggen is: jij maakt het verschiL..
Semra en Ismet, jullie stonden altijd al op de eerste plaats, en dat blijft zo.
Curriculum Vitae
Marjan de Rijke werd geboren op 22 September 1961 te Middelburg. In 1979 behaalde zij
het Atheneum-A diploma aan de Chnstelijke Scholengemecnschap \X'alchercn, cvcneens
te Middelburg. In darzelfdc jaar begon zij in Vlissingen aan dc insemce oplciding voor A-
verpleegkundige. Na het behalen van haar diploma in 1983 ucrkte zij nog twee jaar in
hetzeltde ziekenhuis als gediplomeerd verplccgkundigc op dc atdclmg urologic/
orthopedic /oogheelkunde. In 1985 verhuisde zij naar ecn noordclijkcr gelcgcn eiland
(Schouwen-Duiveland) en werkte aldaar in het klcinc streekziekenhuis te /.icrikzec op dc
afdeling chirurgie/gynaecologic. In 1989 vond zij het njd voor ecn ngoreuzc verandenng
en vertrok zij naar Maastricht om haar heil tc zoeken in dc wetenschap. Van 1989 tot
1993 studeerde zij daar met veel plezier CJezondhcidsvmenschappcn aan dc I'nivcrsiteit
Maastncht, afsnidcerrichnng Theone van de (iezondhcidswetenscluppcn. Tcncindc ook
op het gebied van onderzoek zo breed mogclijk onderlegd tc geraken, volgdc zij in I9').S
de Postdoctorale opleiding F.pidemiologie van het UMCJO aan dc Ynje I'nivcrsitcit tc
Amsterdam. Ondcrdecl van dcze oplciding was ecn ondcrzocksstage, wclke zij vcrrichi
hceft op de afdeling Kankcrregistranc en F.pidemiologie van het lmcgraal Kankcrccntnim
limburg (1K1.) tc Maastricht. Na het bchalen van het diploma werd zij in 19% aangcsteld
als projecrmedewerker op dezc afdebng. Dit is zij blijvcn d«K'n tot 1 okiohcr 2<H)2. Smds
die datum wcrkt zij als onderzoeker op het Pijn Kcntus Centrum in het acadcmisch
ziekenhuis Maastncht. Post-operarieve pijn en pijn bij kankcrjiaticnicn zijn hicr dc
aandachtsgebieden waarop zij wcrkzaam is.

